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Military personnel engage in vigorous PA, which would suggest higher bone mineral 
density (BMD) and lower fracture incidence rates; however, bone injuries are common 
in this cohort.  Imaging devices such as DXA and pQCT scanners have been used in 
addition to serum bone turnover markers (BTM) to describe skeletal responses to 
military training interventions; however, researchers are investigating novel biomarkers 
due to poor injury prediction capabilities of BTM.  Parathyroid Hormone (PTH) and 
sclerostin are two markers that have been predictive of fracture in other populations.  
PTH can cause increased bone resorption and it is a strong predictor of fracture risk in 
postmenopausal women; however, the investigation of this marker in military 
populations has produced confounding results.  Sclerostin is secreted by osteocytes and 
is also a marker of bone resorption; however, to date very few studies have investigated 
the marker’s response to longitudinal exercise in humans.  Purpose: The purpose of this 
study was to determine the effects of an eight week military training intervention on 
PTH and sclerostin serum concentrations, and aBMD of the total body, dual femur, and 
lumbar spine, and bone geometry of the tibia, in healthy, college-aged USMC and 
Naval Reserve Officers’ Training Corps (ROTC) members as compared to a matched 
control group. A secondary purpose was to determine the relationship between PTH and 
sclerostin and bone variables. Lastly, group differences in body composition, upper and 
lower body muscular strength and power measures, and aerobic fitness and their 
relationships to PTH and sclerostin serum concentrations were examined.  Methods:  
Eighteen college-aged ROTC members were matched for sex, age (±2yrs), and body 
mass (±5lbs) to physically active controls.  ROTC participants engaged in an eight week 
xii 
training intervention, while controls made no changes to their physical activity. Total 
body areal BMD (aBMD) and body composition were measured by DXA at the pre, 
mid, and post testing periods.  Regional aBMD of the lumbar spine and hips were 
measured by DXA at the pre and post testing periods. Volumetric BMD (vBMD) of the 
non-dominant tibia was measured by pQCT at the pre and post testing periods.  Serum 
PTH and sclerostin were assessed from pre and post blood draw using commercial 
ELISA kits. Lastly, measures of muscular strength and power were tested at the pre, 
mid, and post testing periods while aerobic capacity was tested pre and post 
intervention. Results:  Both groups decreased total body and regional fat mass (all 
p≤0.047) while only ROTC participants exhibited significant increases in dominant 
femoral neck, and dominant total hip aBMD and BMC (all p≤0.033) after the eight 
week intervention.  No consistent group or time differences were found for pQCT 
variables or biomarker responses.  ROTC members started and ended the intervention 
with greater relative VO2 peak measures and also increased relative VO2 peak 
significantly more than controls (time effect p=0.007; group effect p=0.014).  At both 
time points serum sclerostin demonstrated strong positive correlations with aBMD, 
vBMD, and performance measures in the ROTC group.  Conclusion: An eight week 
military training intervention did not result in skeletal changes suggestive of  increased 
risk for injury as compared to a matched control group. In fact the intervention resulted 
in greater aBMD of the lumbar spine and hip regions in ROTC members. Serum 
biomarker responses were not significantly different over time; however, sclerostin may 
provide additional information regarding skeletal changes in this cohort. 
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Chapter 1: Introduction 
 
Bone turnover is a dynamic process in which the skeletal tissue responds to 
stimuli in order to meet the body’s demands for structural integrity, protection, and 
minerals.  Physical activity (PA) is often viewed as osteogenic because muscle 
contractions and vertical ground reaction forces load the bone, resulting in 
microdamage, which initially signals bone resorption, followed by reparative bone 
formation (1-3).  If the timing between vigorous and potentially damaging PA bouts is 
too short and does not allow for adequate bone formation to occur, it may reduce the 
integrity of the bone and increase the risk for injury (4).  One of the most common bone 
injuries is a fracture, which includes osteoporotic and stress fractures.  Osteoporotic 
fractures are primarily due to reduced mineral matrix, resulting in poor integrity of the 
bone (5); while stress fractures are characterized as cumulative microdamage or trauma 
to the bone, resulting in pain and reduced loading capabilities (6).   
Athletes from a wide variety of disciplines present with stress fractures; 
however, tactical athletes are of special concern.  The term tactical athlete refers to law 
enforcement, military, and rescue professionals who require unique parameters of 
physical fitness and technical skills (7).  Military personnel engage in vigorous PA, 
which would suggest higher bone mineral density (BMD) and lower fracture incidence 
rates; however, bone injuries are common in this cohort (8-11).  According to the U.S. 
Government Accountability Office, bone injury is a significant contributor to attrition 
rates within the first six months of military service (12).  Even recruits who fully 
recover from these injuries are at significantly greater risk for another fracture during 
subsequent service (10.6% incidence within one year of injury, versus 1.7% in injury-
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free recruits), which poses a financial burden and combat risk (13).  The Department of 
Defense estimates that bone injuries in military personnel cost over $100 million 
annually in medical care and lost productivity (14).  Studies conducted on American, 
Israeli, and Finnish army recruits reported that fracture incidence rates during basic 
training range from 7-31% (15-17).   
The two most common imaging techniques used in the assessment of bone 
quality are dual-energy x-ray absorptiometry (DXA) and peripheral quantitative 
computed tomography (pQCT) (18). Beck et al. (19) used both DXA and pQCT to 
describe the differences between male and female military recruits who suffered 
fractures.  Recruits who presented with fractures had poorer physical fitness, smaller 
muscle cross-sectional area (mCSA) and bone strength indices of the thigh and tibia 
compared to those military recruits who did not report fractures (19).  In female Naval 
Academy recruits, low BMD, as measured by DXA, was strongly correlated with  
fracture risk during eight weeks of training (8).  These imaging methods provide 
valuable assessments of bone density and quality. 
Bone metabolism at the cellular level, however, can be better understood using 
serum bone turnover markers (BTM).  BTM are circulating biomarkers that are 
commonly used in conjunction with imaging devices to better describe acute and 
chronic skeletal adaptations (20).  BTM have been identified for both resorption and 
formation processes and can be assayed from small samples of serum.  For example, 
biomarkers such as procollagen type I N propeptide (PINP) and bone-specific alkaline 
phosphatase (bone ALP) are commonly used as markers of bone formation, while C-
telopeptide of type I collagen (CTX-I) and tartrate-resistant acid phosphatase 5b 
3 
(TRAP5b) are used to describe bone resorption (21).  PINP is a class of peptides that is 
specific to proliferating osteoblasts, the cells responsible for building bone (22), and 
bone ALP is an enzyme produced by osteoblasts that aids osteoid formation and 
mineralization (23).  When osteoclasts resorb bone, a variety of proteins are released; 
however, 90% of these proteins are fragments of type I collagen.  CTX-I is a product of 
type I bone collagen degradation and is used as a bone resorption marker (24).  An 
additional bone resorption marker used is TRAP5b.  TRAP5b is secreted from the 
osteoclasts ruffled edge during migration from one resorption pit to another, and is used 
as a marker of mature osteoclast number (25). 
Several studies have identified BTM as strong correlates of stress fracture in 
clinical populations (26, 27); however, the evidence for BTM predictive power is 
inconsistent within athletic and military populations.  Bennell et al. (28) followed nearly 
100 track and field athletes for 12 months to evaluate the role of BTM in the 
pathogenesis of stress fractures.  Those who suffered fractures did not have different 
serum concentrations of BTM at any point during the 12 months compared to those who 
remained injury free (29).  Prospective studies have followed military members 
throughout training periods and found that BTM were strong predictors of injury status 
(30), while other prospective studies demonstrated no relationship (3, 17, 31).  
Inconsistencies in these results might stem from the heterogeneity of sex, age, and type 
of military training in each of the populations that were followed.     
Novel biomarkers need to be investigated for potential viability as sensitive 
injury predictors in addition to the use of imaging machines and BTM. Parathyroid 
hormone (PTH) is being investigated as an endocrine regulator of bone in military 
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cohorts. PTH is a major mediator of serum calcium ion concentrations, with target 
tissues being the kidneys and bone (32).  PTH is secreted by the parathyroid glands in 
response to calcium-sensing receptors detecting decreases in serum calcium ion 
concentrations (33).  In bone, PTH stimulates osteoclasts to resorb bone mineral, 
increasing serum calcium ion concentrations.  In the kidneys, PTH signals the increase 
in proximal tubular resorption of calcium and formation of vitamin D, while 
simultaneously increasing the amount of phosphate excreted in an attempt to restore 
calcium homeostasis (32). Prospective studies have found that PTH is chronically 
elevated post basic training in male (17) and female (34) military recruits, while it did 
not change in elite male combat trainees (31), and it decreased in male and female 
recruits over a four-month basic training period (35).  
Sclerostin is another biomarker that is being used to describe bone metabolism.  
Sclerostin is a glycoprotein secreted from osteocytes and acts as a negative regulator of 
bone formation via Wnt signaling inhibition (36, 37).  The Sclerostin (SOST) gene 
product is used by osteocytes to fine tune the skeletal response to mechanical loading 
(38).  Animal models have shown that with increased mechanical loading sclerostin 
production is reduced (39).  In humans, many cross-sectional studies have demonstrated 
acute increases in sclerostin post exercise; however, many of these studies do not 
account for plasma volume shifts which could result in inaccurate calculations of the 
sclerostin response (38, 40).  The few longitudinal studies that exist demonstrate that 
with increased exercise, sclerostin concentrations decrease, much like the animal data 
suggests (41, 42).  In postmenopausal women, studies have shown with regression 
analysis that higher concentrations of sclerostin are associated with increased fracture 
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risk; however, its usage in the description of military personnel bone health is currently 
nonexistent (43, 44).     
Body composition and fitness levels also play a role in bone injury for military 
personnel.  The negative correlation between muscle mass and fracture risk is well 
documented in a variety of populations (45-47).  Naval Academy students who 
presented with fractures during basic training exhibited four times more body mass loss, 
had lower total body bone mineral content (BMC), and thigh mCSA compared to those 
students who remained injury free (8).  Protective factors for bone overuse injuries 
include aerobic fitness (48), lower body mCSA (49), and performing weight-bearing 
exercises (50).  Newly implemented training regimens that combine aerobic fitness and 
muscular strength/power have been shown to be an important tool in the reduction of 
military fracture rates, especially in the United States Marine Corps (USMC) and Navy 
(6, 50, 51).  The exact relationships between aerobic fitness and muscular 
strength/power and biomarkers used for fracture prediction in military populations is 
understudied. 
Purpose 
The purpose of this study was to determine the effects of an eight week military 
training intervention on PTH and sclerostin serum concentrations, and areal bone 
mineral density (aBMD) of the total body, dual femur, and lumbar spine, and bone 
geometry of the tibia, in healthy, college-aged USMC and Naval Reserve Officers’ 
Training Corps (ROTC) members as compared to a matched control group. A 
secondary purpose was to determine the relationship between PTH and sclerostin and 
bone variables. Lastly, group differences in body composition, upper and lower body 
6 
muscular strength and power measures, and aerobic fitness and their relationships to 
PTH and sclerostin serum concentrations were examined.  ROTC members ranged 18-
29 years old and all completed mandatory group training sessions that included 
endurance and resistance exercises. 
Research Questions 
1. Will an eight week military training intervention period (MTIP) significantly 
alter the PTH and sclerostin serum concentrations, and will these responses be 
different from those in a physically active age- and body-mass matched control 
group who does not participate in the MTIP? 
2. Will an eight week MTIP result in significant total body aBMD changes and site 
specific aBMD changes at the lumbar spine and dual femur, and will these 
changes be different from those in a physically active age- and body-mass 
matched control group who does not participate in the MTIP? 
3. Will an eight week MTIP alter bone content, geometry, and strength of the 4%, 
38%, 66% non-dominant tibia sites, and will these changes be different from 
those in a physically active age- and body-mass matched control group who 
does not participate in the MTIP? 
Hypotheses 
1. PTH serum concentrations will significantly increase, while serum sclerostin 
concentrations will decrease in ROTC members but not in controls. 
2. Total body and site specific aBMD will significantly change in ROTC members 
but not in controls. 
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3. Significant skeletal geometry changes of the 4%, 38%, 66% non-dominant tibia 
sites will occur in ROTC members but not in controls. 
Sub Questions 
1. Will there be significant relationships between serum PTH and sclerostin and 
total body and site-specific aBMD, bone free lean body mass (BFLBM) and fat 
mass (FM)? 
2. Will there be significant relationships between serum PTH and sclerostin and 
4%, 38%, 66% non-dominant tibia sites measures of bone strength and 
geometry? 
3. Will there be significant relationships between serum PTH and sclerostin and 
muscular power and strength? 
4. Will there be significant relationships between serum PTH and sclerostin and 
aerobic capacity? 
Sub Hypotheses 
1. ROTC members will demonstrate significant increases in aBMD, BFLBM and a 
significant decrease in FM as compared to controls, and these changes will have 
significant relationships with biomarkers. aBMD and BFLBM will be positively 
correlated and FM and serum PTH concentrations and will be negatively 
correlated with serum sclerostin concentrations. 
2. ROTC members will demonstrate significant increases in measures of bone 
strength and quality at the 4%, 38%, 66% non-dominant tibia sites and these 
changes will have significant negative correlations with PTH and sclerostin. 
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3.   ROTC members will demonstrate significant increases in muscular strength and 
power measures as compared to controls, and these changes will have significant 
positive correlations with PTH and negative correlations with sclerostin. 
4.   ROTC members will demonstrate significant increases in aerobic fitness as 
compared to controls, and these changes will have significant positive 
correlations with PTH and negative correlations with sclerostin. 
Significance of the Study 
Military personnel who sustain a stress fracture during training are removed 
from training for an average of 62 days (52).  In fact, during Marine Corps basic 
training, the single most powerful predictor of discharge is a stress fracture, with a four-
fold increased rate of discharge in soldiers who suffered from a stress fracture as 
compared to their counterparts who remain fracture free (53).  Researchers in this area 
suggest that the current methods of fracture prediction in this population are severely 
lacking, resulting in an underestimation of the impact of stress fractures in military 
populations; thus there is a need for investigation of additional biomarkers to provide 
more predictive power (51).  PTH and sclerostin may provide new information to 
clinicians regarding fracture etiology in military populations. This study provided 
scientific evidence for how these biomarkers and bone responded to an eight week 
MTIP in college-aged USMC and Naval ROTC members as compared to controls.  
Additionally, this investigation characterized the relationship between these biomarkers, 
and parameters of bone health, body composition, muscular strength and power, and 
aerobic fitness.  
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Assumptions 
1. All participants gave maximal effort during the strength and aerobic capacity 
testing sessions. 
2. All participants provided accurate and truthful information for all 
questionnaires. 
3. All participants were fasted for at least eight hours and rested at least 24 hours 
prior to blood draws. 
Delimitations 
1. The findings of this study are applicable only to healthy, college-aged, ROTC 
members who undergo the same military training periods and their matched 
controls. 
2. The participants were recruited only from the University of Oklahoma. 
Limitations 
1. Nutritional status and prescreening fitness levels were not controlled; however, 
calcium intake was measured at the pre testing period. 
2. Unstructured physical activity was not controlled, but was quantified by 
questionnaires for both ROTC members and controls. 
3. All ROTC members completed the same exercises but the load, repetitions, and 
relative intensities were not uniform.   
Operational Definitions 
Areal Bone Mineral Density (aBMD): aBMD (g/cm²) is calculated as bone mineral 
content (g) divided by bone area (cm²) as measured by DXA (54). 
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Body Composition: Is a mathematical representation of tissue types within the human 
body: normally expressed relative to body mass, such as percent fat (55). 
Bone Mineral Content (BMC): DXA-derived BMC values refer to the amount of 
mineral (g) within a specified region of analysis.  pQCT-derived BMC values refer to 
the amount of mineral per unit of axial bone length (mg/mm) (56). 
Bone Remodeling: An integrated process where different types of specialized bone 
cells coordinate the resorption and formation of new bone, also referred to as bone 
metabolism (57).  Bone resorption is the process of degrading skeletal matrix, primarily 
performed by osteoclasts.  Bone formation is the process of binding new skeletal 
matrix, primarily performed by osteoblasts (57). 
Bone Strength Index (BSI):  BSI is the product of cross-sectional moments of inertia 
(mm⁴) and cortical volumetric density (mg/mm3) (58). 
Bone Turnover Makers (BTM):  Are circulating biomarkers that are commonly used 
to describe bone cell activity resulting in either bone formation or resorption (20, 59).   
Cortical Area: The area of pixels identified as cortical by the pQCT (mm²) (58). 
Cortical Bone: The primary structure that provides rigidity to the skeleton.  It is dense 
bone and located toward the outer part of the bone ending at the periosteum (60). 
Cortical Thickness: is the thickness of all pixels identified as cortical bone by the 
pQCT software (mm) (61). 
Counter Movement Jump: Is a functional jumping task in which a squat to a self-
selected depth is performed prior to the explosive vertical jumping movement is 
competed (230). 
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Dual Energy X-Ray Absorptiometry (DXA): DXA uses the attenuation of x-rays 
through tissues to measure the composition of that tissue.  This type of measurement is 
areal, only providing a two-dimensional representation of the scanned area.  DXA 
scanners can measure total body and site-specific bone mass, fat mass, and bone-free 
lean body mass (54). 
Endosteal Circumference: is the thin inner membrane that surrounds the medullary 
cavity and is measured by distance (mm) (61). 
Muscle Cross-Sectional Area (mCSA): is the total area of a muscle (mm²) (55). 
One-Repetition Maximum Effort: (1RM) is the maximal amount of external load 
ones musculoskeletal system can overcome (231). 
Osteoblast: A specialized bone surface cell responsible for bone formation (59). 
Osteoclast: A specialized bone surface cell responsible for bone resorption (59). 
Osteocyte: A specialized mechanosensitive bone cell embedded within the mineral 
matrix, primarily responsible for signaling the skeletal tissue through an extensive 
lacunocanalicular network of dendritic processes (59). 
Osteopenia: is a condition of lower than normal BMD indicated by a T-Score of ˗1.1 to 
˗2.4 as measured by DXA, in adults 50 years or older. In males and females younger 
than 50 years, Z-scores are used to classify bone status instead of T-scores. A Z-score ≤ 
−2.0 is defined as having a BMD value below the expected range for age (62). 
Osteoporosis: is a condition of low BMD resulting in reduced bone strength and 
increased risk of bone injury.  It is normally indicated by a lumbar spine, total hip, or 
femoral neck T-Score of ≤ ˗2.5, as measured by DXA in adults 50 years or older (62). 
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Parathyroid Hormone (PTH): is a peptide hormone secreted from the parathyroid 
glands in response to calcium-sensing receptors detecting decreases in plasma ionized 
calcium concentrations and plays a pivotal role in calcium homeostasis and 
subsequently the bone remodeling process (63).   
Peripheral Quantitative Computed Tomography (pQCT): pQCT uses the 
attenuation of x-rays through tissues to measure the composition of that tissue.  This 
type of measurement is volumetric due to multiple slices being combined (mg/cm³) and 
can provide a determination of cortical and trabecular bone in addition to mCSA (54). 
Periosteal Circumference: is the thin outer membrane that surrounds the cortical shell 
and is measured by distance (mm) (61). 
Polar Moment of Inertia (iPolar): iPolar estimates the ability of the bone structure to 
withstand torsional forces (cm⁴) (56). 
Regular Menstrual Cycle: A recurring menstrual cycle without more than three 
consecutive months of disruption (64). 
Sclerostin: is a glycoprotein secreted by osteocytes and a SOST gene product, which 
acts as a negative regulator of bone formation via Wnt signaling inhibition (36).   
Stress Fracture: is cumulative microdamage or trauma due to repetitive loading 
coupled with insufficient rest periods, resulting in impaired structure integrity (6).   
Stress-Strain Index (SSI): SSI combines both measures of bone geometry (section 
modulus) and quality (cortical vBMD (mm³)) to provide a more comprehensive 
measure of bone integrity (58). 
T-Score: is the number of standard deviations above or below the mean BMD for the 
young Caucasian female reference population (65). 
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Trabecular Bone: Also referred to as cancellous bone, is a spongy mineral matrix with 
large surface area and metabolic activity.  It is located towards the inner part of bones 
and near the distal ends of long bones (60). 
Maximal Volume of Oxygen Consumption: Maximal volume of oxygen (VO2 max) 
consumption refers to the maximal volume of oxygen being consumed during exercise.  
VO2 max is defined at the maximum amount of oxygen that can be consumed during 
maximal effort exercise divided by kg of body mass per minute; while VO2 peak is 
defined as the two greatest reported VO2  values within 30 seconds of each other during 
a maximal effort exercise divided by kg of body mass per minute (229). 
Volumetric Bone Mineral Density (vBMD): is the quotient of BMC and the total 
cross-sectional area of bone.  Cortical vBMD and trabecular vBMD can also be 
measured by calculating the quotient of BMC and the total cross-sectional area of the 
particular bone type (mg/cm³) (56). 
Z-Score: is the number of standard deviations that a participant’s aBMD is away from 











Chapter 2: Literature Review 
 
Introduction 
Having a stable bone mass requires balance between the activity of bone 
forming cells and bone resorbing cells, the osteoblasts and osteoclasts, respectively.  A 
third bone cell type, osteocytes, are located in the mineralized bone tissue and can 
detect injury and mechanical strain (66).  Many injury and disease states can be 
attributed to dysfunctional signaling pathways or disproportionate activity of these three 
cell types.  For example, Van Buchem disease (VBD) is characterized by uncontrolled 
bone growth.  The primary contributor is a dysfunctional SOST gene that cannot 
adequately produce sclerostin, which serves as a potent bone formation inhibitor (67).  
Injuries and diseases due to imbalanced bone turnover resulting in low bone mass are 
more common.  For instance, osteoporosis is a progressive disease characterized by low 
bone mineral density (BMD), high rates of bone turnover, and reduced structural 
integrity (68). Unlike VBD, there is no single cause of osteoporosis, as genetic and 
dietary factors combined with physical activity (PA) and hormonal levels play vital 
roles in the development and progression of the disease.   
Low BMD and poor bone quality reduces the bone’s ability to withstand stress 
and increases the risk for bone injuries (69).  Research has shown that pharmacological 
treatments and physical activity (PA) can both have positive effects on low BMD.  One 
of the most common drug strategies is prescribing bisphosphonates, which has been 
shown to successfully reduce the risk of fractures; however, this class of drug is not 
suitable for all populations and has side effects to consider (68).  PA-induced 
mechanical stress signals bone formation when the stimuli meet the loading profile 
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criteria and exceed the minimum threshold (70, 71).  With loading, the skeleton sustains 
microdamage that is repaired, resulting in a greater strain tolerance; however, certain 
types of PA and loading profiles do not always allow for an adequate amount of repair.  
When the microdamage cannot heal in the midst of additional loading, a stress fracture 
may occur. 
 Older adults are not the only populations where low BMD and fractures are 
observed; many athletic and military populations also share these characteristics.  
Military personnel often engage in PA, which should result in higher BMD; however, 
bone injuries are common.  Being female has been presented as the primary risk factor 
for bone injury in military recruits; however when age, fitness, and race are controlled, 
sex differences became non-significant (9).  In military personnel, how the changes in 
bone density, geometry, strength, and injury risk are related to age, sex, dietary intake, 
and measures of physical performance are currently not well characterized. 
Bone Physiology  
 Skeletal homeostasis is a dynamic and integrated process that involves a wide 
variety of cell types and signaling pathways.  The genetic blueprint for bone is 
contained within the bone cells.  There is also an epigenetic component of skeletal 
design that is directed by the chemical milieu of the cell’s internal environment and the 
mechanical forces exerted on the bones.  Together, these forces shape the bone until it 
can meet the loading requirements applied to it (72).  There are three primary cell types 
that work in unison to engineer bone’s structure: osteocytes, osteoblasts, and 
osteoclasts.  The way that these cells interact also determines the spatial orientation and 
extent of mineralized matrix.  These structural differences can be observed in the two 
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different types of bone, cortical and trabecular.  Highly integrated signaling pathways 
regulate how these bone cells function throughout developmental, maintenance, and 
disease stages.  
Osteocytes are distributed throughout the skeletal mass, connected to each other 
through dendritic processes, much like axons.  Specifically, osteocytes make up nearly 
95% of all bone cells and are an integral part of these signaling pathways and bone’s 
mechanosensitivity.  These processes usually radiate from the osteocyte towards the 
bone surface and towards vasculature. The small openings within the bone in which  
osteocytes are housed are called lacunae, while the dendrites travel through a series of 
tunnels called canaliculi. These cells create a mechnosensitive detection system called 
the lacunocanalicular network that is partially responsible for converting mechanical 
stimuli into chemical signals.  This process is also known as mechanotransduction.  
Because of this particular anatomy, osteocytes have been viewed as the primary 
signaling cell to cue osteoblast and osteoclast activity (73).   
Osteocytes are only fully functional after three distinct stages of morphology.  
First, osteoprogenitor cells within the bone marrow will differentiate into osteoblasts.  
Secondly, while functioning as osteoblasts, these bone-lining cells will transition into an 
osteoid-osteocyte, that has the unique capability of actively modeling matrix while also 
calcifying that same matrix.  This cell will then shrink in size by approximately 30% 
and settle into a lacuna where the final transition to a mature osteocyte occurs (74).   
 The lacunocanalicular network utilizes each aspect of osteocyte anatomy to 
serve as the primary mechanosensor of the bone, which can signal both osteoclasts and 
osteoblasts.  For instance, actin proteins act like tethers to anchor the osteocytes within 
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the lacunae.  When fluid shifts occur, due to mechanical loading or vibration, shear 
forces can be sensed by these actin proteins, the primary cilium, and the osteocyte cell 
membrane, that will result in stimulation of osteoblast activity (74).  Additionally, at the 
far reaches of the osteocytes' dendrites, the tips are covered in specialized gap junctions 
that are also sensitive to shear forces and can relay chemical messages back to the 
osteocyte about the mechanical forces that matrix is experiencing.  Osteocytes also can 
signal osteoclasts to increase bone resorption in the absence of mechanical loading 
signals.  Along the dendritic processes, NF-kappaB ligand (RANKL) expression is 
increased when the bone is unloaded, which signals osteoclasts to initiate the formation 
of resorption pits (75, 76).  Traditionally, it has been thought that osteocytes only signal, 
and it is the osteoblasts and osteoclasts that are responsible for matrix modification.  
Nearly 50 years ago, it was hypothesized that osteocytes might have the capability of 
mineralizing their surroundings, more recently it has been shown that osteocytes can 
also enlarge their lacunae and canaliculi by a few angstroms (77, 78).  These small 
alterations could enact large changes for the microarchitecture and strength of the bone 
because the surface area of the lacunocanalicular system is several orders of magnitude 
greater than the bone surface, where osteoblasts and osteoclasts have their effects (76). 
 It is not well characterized why osteocytes develop from their osteoblast 
precursor.  However, the mechanisms leading from mesenchymal stem cells (MSC) to 
osteoblastogenesis are tightly regulated by a wide variety of factors.  In fact, there are 
five primary cytokines that are involved with osteoblast differentiation: the Hedgehog 
proteins, bone morphogenetic protein (BMPs), transforming growth factor-β (TGF-β), 
parathyroid hormone (PTH), and Wnts in addition to the master switch for 
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osteoblastogenesis, Runx2.  Runx2 knockout (KO) mice are not capable of producing 
osteoblasts and form cartilaginous skeletons that are void of mineralized matrix (79).  
Runx2 also targets the transcription factor Osterix (Osx).  Osx KO mice also lack 
osteoblasts and have a many downstream pathways that are dysfunctional and often 
result in death (80).  Runx2 cooperates with other transcription factors to control BMP-
induced osteoblast gene expression and creates a positive feedback loop to regulate 
osteogenesis (81). While downstream targets of Runx2 also interact with TGF-β, the 
Hedgehog family of proteins, and Wnts, fine-tune osteoblast and osteoclast 
development, activity, and apoptosis (81). 
 Bone cells work in a coordinated manner to repair microdamage and replace old 
bone with new mineral deposits.  Mature osteoblasts’ primary purpose is to synthesize 
osteocalcin and osteopontin and then adhere these proteins to the exposed cross-linked 
collagen.  Osteoblasts also play a pivotal role in mineralizing the cartilaginous skeletal 
during growth.  Osteoclasts, on the other hand, are members of the monocyte-
macrophage family from bone marrow.  Two cytokines are responsible for 
osteoclastogenesis.  The first is RANKL, and the second is macrophage-colony 
stimulating factor (M-CSF).  RANKL is the key cytokine for osteoclast formation, 
while M-CSF contributes to the proliferation and survival of the osteoclast (82).  
Osteoclasts have a unique ability to create a microenvironment that maintains a pH of 
around 4.5, which is needed to release calcium phosphate and other organic compounds 
from the bone surface.  These molecules are then further degraded by cathepsin K, 
before exiting the osteocyte (83, 84).  The careful interaction between osteoblasts and 
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osteoclasts is how bone serves as the primary calcium repository in the body, and can 
quickly store or mobilize minerals. 
Bone Metabolism 
 
Several controllable factors have been implicated with bone status, such as diet, 
PA, and hormone levels; however, major uncontrollable factors such as genetic 
influences, age, and sex have also been identified.  For instance, several twin and family 
studies have demonstrated that 50-85% of the variance observed in peak aBMD may be 
attributed to uncontrollable genetic factors (85).  Age is a major confounder in skeletal 
health; however, the exact mechanisms are difficult to characterize due to the vast array 
of dysfunction that is associated with an aging individual. Similarly, being female is a 
factor for reduced aBMD and the differences in bone strength, geometry, and density 
have very strong links to sex hormones.  Therefore, it is nearly impossible to target one 
factor without the consideration of many others. 
Age-related factors in bone health can be separated into time frames of bone 
development and growth, maintenance, and the age-related bone loss that occurs after 
the fifth decade of life.  Even before the age of 2 years, some skeletal traits have been 
established (86). Once children reach the early stages of puberty, large differences can 
be observed in bone geometry; however, once puberty is over, the differences in BMD 
are drastically reduced, suggesting that the variances observed in bone strength are 
more likely attributable to bone geometry instead of bone density (87).  Skeletal 
geometry is sensitive to alterations at different time points and is site-specific.  For 
example, the subperiosteal surface of long bones is most sensitive to alterations in 
mechanical loading during childhood and early adolescence, but the endocortical 
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surface is more mechanosensitive during puberty (88, 89).  This is an issue with 
childhood inactivity and might affect each sex differently. How bones adapt during the 
developmental and growth stage can have lasting effects. For instance, the differences 
observed in bone size and mass around an age-specific mean is large; 1 SD is equivalent 
to 10-15% of the mean.  The variance in the rate of bone loss is significantly smaller as 
1 SD is only about 1% of the mean.  This difference suggests that bone properties that 
are established by the end of maturity are significantly more important determinants of 
bone injury rates in adulthood than differences in the rates of bone loss towards the end 
of life (90).  In 2000, Beck et al. (19) demonstrated that male and female army recruits 
that were age- and fracture-incidence matched, had different bone geometry.  Female 
fracture cases had thinner cortices, while male fracture cases had smaller subperiosteal 
diameters, suggesting that the bone geometry developed in the early years may have 
been important factors in stress fracture etiology as adults.   
Both men and women experience a progressive decline in BMD, which starts as 
soon as peak BMD is reached; therefore advancing age is a risk factor for fracture, 
especially for those over the age of 50 (91).  As the aging process occurs, many 
signaling pathways and mechanisms become dysfunctional that can increase the risk for 
low BMD and subsequent bone injury.  Reactive oxygen species (ROS), apoptosis, 
hormonal influences, and macroautophagy are some important factors to consider (91).  
ROS are responsible for the oxidation of molecules, creating oxidative stress. This 
oxidative stress is managed under normal conditions by a series of antioxidant 
scavengers; however, as the aging process continues, antioxidant activity decreases and 
the effects of ROS become more evident.  Mice deficient in superoxide dismutase 
21 
(SOD), a potent antioxidant, present with decreased BMD, osteoblast and osteoclast 
numbers as compared to wild-type mice (92).  The forkhead box O (FOXO) family of 
transcription factors are also ROS scavengers.  ROS production is increased and bone 
loss is observed, in FOXO KO mice models.  This is due to both a decreased number of 
osteoblasts and an impaired Wnt-β-catenin signaling pathway (93).  RANKL is also 
upregulated with aging, resulting in increased apoptosis of osteocytes which inhibits 
proliferation of osteocytes and increases osteoblast apoptosis (94).  Lastly, 
macroautophagy, or the process of recycling damaged organelles and proteins, can 
become dysfunctional with aging.  A series of macroautophagy-related genes specific to 
osteoclasts, osteoblasts and osteocytes have been deleted in mice; results demonstrate 
drastically altered bone homeostasis (95).   
Hormone concentrations begin to elicit effects on bone morphology during the 
prepubertal stage and continue to have pronounced effects throughout the lifespan.  
Although there are many hormones that are important to bone homeostasis, only three 
will be discussed here: estrogens, testosterone, and parathyroid hormone (PTH).  
Estrogen concentrations, in males and females, play a pivotal role in early bone 
development; however, the main estrogen of interest is estradiol (E2).  Increased E2 
during adolescence have been shown to dictate the amount of viable ERα, which is 
partially responsible for the mechanosensitivity of the bone (96, 97).  Subsequently, 
these increased E2 levels partially explain the enhanced sensitivity to exercise and PA 
during the pre-pubertal stages in males and females; however, the sex-specific changes 
in bone geometry are not the same.  During puberty, males have greater periosteal 
apposition, which leads to increased cortical thickness.  Girls have decelerated 
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periosteal apposition, in addition to no changes in medullary cavity size, resulting in 
bone that is smaller than boys, but with a similar cortical thickness (98).  High levels of 
E2 in post-pubertal females is thought to promote this endosteal apposition, which 
partly explains the higher cortical densities observed in females as compared to males 
(86, 99).  These geometric alterations to bone, periosteal apposition specifically, result 
in the optimization of bone strength without adding excess material.  Since males have 
greater periosteal apposition than females before and during puberty, it stands to reason 
that this is a major contributing factor to the greater bone strength observed in males 
across the lifespan (86).  
E2 levels are drastically reduced during the menopausal transition in women.  
The cessation of menstruation occurs at about 48-50 years of age in most women and 
results in unbalanced and aggressive bone turnover, especially in trabecular bone.  
Indices of bone resorption are twice as high in postmenopausal women (PMPW), as 
compared to premenopausal women, while the bone formation markers are only 50% 
elevated above premenopausal levels. This skewed ratio leads to rapid bone resorption 
and increased risk for low BMD and bone injury (100). At the cellular level, it has been 
shown with a decrease in E2 levels the lifespan of osteoblasts and osteocytes decreases 
while the osteoclasts remain viable for longer (101).  This period of accelerated bone 
loss lasts approximately 5-10 years and is followed by a second phase of continuous 
bone loss.  Hormone replacement therapies (HRT) have shown to help women maintain 
much of the bone that is lost during the accelerated bone loss phase and reduce the risk 
of fractures (102).  During this slower phase, cortical and trabecular bone loss is nearly 
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identical.  This secondary phase also matches the bone loss rates observed in males 
(103). 
Bone loss in males from middle age to the end of the lifespan show slow and 
progressive trabecular and cortical loss. However, since males do not have a 
menopausal transition to navigate, the overall loss in bone is significantly less than in 
females. Relative to PMPW, elderly men lose about half as much bone and sustain a 
third fewer fragility fractures (104). Males experience a two-fold increase in sex 
hormone binding globulin (SHBG) as they age, which results in a substantial decline in 
the bioavailability of sex hormones. Specifically, reductions around 47% in estrogens 
and 64% in testosterone were observed based on data from the Rochester, MN cohort 
(105).  Although testosterone is often considered the primary sex hormone for males, 
estrogen concentrations have stronger correlations to BMD at several sites in males, 
suggesting that the bioavailability of estrogen is a more potent factor for skeletal 
homeostasis (106). Testosterone supplementation studies have tried to characterize the 
hormone’s effects on bone mass; however, it is difficult to elucidate a true mechanism 
as testosterone can also be aromatized into estrogen (107). 
PTH levels also change throughout the aging process and can contribute to the 
age-related bone loss observed in both sexes.  The decreases in serum E2 concentrations 
that occur during menopause will result in an increase in serum calcium concentrations 
due to increased bone resorption (108).  Increased bone resorption will result in an 
increase in serum calcium concentrations and cause a compensatory decrease in PTH 
secretion (108).  An opposite PTH response is observed in males and females in the 
later years of life, resulting in secondary hyperparathyroidism (109). The mechanisms 
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behind this chronic elevation in PTH in females are twofold; first is reduced active 
vitamin D, and the second is altered calcium balance due to prolonged E2 deficiency.  
Active vitamin D synthesis is reduced due to decreased sun exposure and the loss of  
intestinal vitamin D receptor sensitivity (110).  With less active vitamin D, calcium 
absorption in the small intestine will decrease causing PTH secretion.  The second 
factor is chronic E2 deficiency.  Estrogens are needed to maximize the reabsorption of 
calcium from the kidneys and, without its effects, more calcium is excreted (111).  
Together with PTH, vitamin D aids to regulate calcium concentrations that are vital to 
skeletal health (91).  Typically, about 200 mg of calcium are removed from the skeleton 
and replaced each day (112).  As previously described, reduced serum calcium 
concentrations caused by insufficient dietary intake or increased renal excretion will 
result in bone resorption via PTH.  Chronically elevated PTH has been shown to be 
catabolic to the bone and can increase the risk for low BMD and bone injury (113). 
Dietary calcium at sufficiently high levels of 1,000 mg/day have been shown to reduce 
the bone remodeling rate by 10-20% in older adults; however, as the aging process 
progresses, the vitamin D receptors (VDR) in the intestine become less sensitive, which 
may contribute to reduced bone mass over time (110). Additionally, the concentrations  
of 7-dehydrocholesterol, the precursor to vitamin D, is reduced in aging populations, 
resulting in less vitamin D synthesis from sunlight exposure (114).  Adequate vitamin D 
and calcium levels have been shown to be associated with increased bone mass, 
strength, muscle mass, gait speed, balance scores and reduced risk of fractures and falls 
in both elderly men and women (115-117).   
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Bone health can be greatly affected by inadequate vitamin and mineral 
consumption, such as vitamin D, calcium, phosphorus, and magnesium (118).  Good 
sources of these vitamins and minerals include fruits and vegetables that are high in 
phytochemicals.  Additionally, fruits and vegetables can act like antioxidants and 
decrease the aforementioned detriments of ROS on bone (119).  Fruit and vegetables 
also help to maintain a less acidic environment, which can have a positive effect on 
bone by reducing calcium resorption (120).  Protein, on the other hand, has been shown 
to increase the acid load to bone, which could result in the mobilization of calcium from 
bone; but in general high protein diets have been associated with increased BMD and 
decreased fracture risk (120).  Both macro- and micro-nutrients are important for 
skeletal health and are often inadequate in athletes, especially females (121, 122).  Low 
energy availability uncouples bone turnover and suppresses bone formation (123).  This 
caloric deficit may be intentional due to disordered eating patterns and/or excessive 
exercise.  This phenomenon, once thought to only occur in females, termed the female 
athlete triad, has now been adapted to be called relative energy deficiency in sports 
(REDS) to expand this concept to all athletes (124).   
Drug abuse can also adversely affect bone health; two drugs of common use in 
the general population and military personnel are alcohol and tobacco.  It has been 
demonstrated that alcohol has a dose-dependent effect on bone with moderated 
consumption posing beneficial attributes while excessive consumption can lead to 
decreased BMD (125).  Too much alcohol has been shown to increase osteocyte 
apoptosis, oxidative stress, and Wnt signaling pathway dysfunction (125).  A dose-
dependent relationship between tobacco use and bone health is well documented; 
26 
however, since tobacco causes dysfunction in so many systems throughout the body, a 
clear mechanism has not yet been characterized (126, 127).   
Mechanotransduction 
Bone is sensitive to mechanical stimuli; however, certain loading profiles are 
more osteogenic than others.  Over 100 years ago, Roux and Wolff proposed that bone 
architecture is determined by mathematical laws; then Pauwels, Thompson, Turner, 
Frost, Hert, Rubin, McLeod, and others continued to further characterize how bone is a 
dynamic tissue capable of adapting to loads (71, 128, 129).  Although many scientists 
over the past century have added information to the characterization of osteogenic 
loads, two of the most prolific contributors were Turner and Frost (71, 72, 130, 131). 
Turner described three basic rules that a load or stimulus must meet or exceed in 
order to elicit an anabolic skeletal response (130).  First, the load should be a dynamic 
movement instead of static.  Second, short durations of loading are sufficient to induce 
changes.  And lastly, bone cells will adapt to the stimuli over time, thus requiring a 
progression or novelty of the stimuli.  In conjunction with these rules, Frost elaborated 
on Turner’s rules with the introduction of the mechanostat theory.  This theory suggests 
that bone cells have a minimum and maximum threshold of stimuli that will determine 
the bone response of either conservation of bone mass or the alteration of bone mass by 
formation or resorption (71).  Additionally, four specific aspects of the loading profile 
may be manipulated to satisfy the aforementioned laws: frequency, magnitude, 
duration, and rest.  The mode to which a load is transmitted to the skeleton will alter 
these variables and in turn dictate the cellular response.   
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 Arguably, one of the most important controllable factors for bone strength is 
skeletal muscle capacity. For instance, years after paraplegia or paralysis, bones in the 
paralyzed lower extremities lose nearly 40% of their strength and mass as compared to 
the upper body (132).  Skeletal muscle has the ability to apply or attenuate stress to the 
skeleton.  The application of stress is most notable during force production at the ends 
of the long bones.  For instance, even during normal locomotion over 2 kg of force 
generated by the muscles is required to move each kg of body weight (133).  In certain 
regions of the body, bone loading is increased by an internal muscular force as a result 
of contraction; however, this contraction also decreases the bone loading observed in 
other regions of the bone (134, 135).  Depending on the anatomical locations of the 
points of insertion and origin, paired with pennation angle, a muscle can provide 
compression, tension or bending strains to a bone.  Additionally, if an external load is 
applied to the bone from vertical ground reaction forces (vGRF), the compensatory 
muscle contraction can reduce the compression, shear, torsional, or bending forces 
applied to the long bones.  Individuals, who vary in muscle strength, will be able to 
produce and redistribute different magnitudes of load (19).  This result suggests the 
same exercise, being performed by two people of unequal muscular strength, may result 
in unequal osteogenic effects. 
To investigate the role of skeletal muscle load attenuation and fatigue, Milgrom 
and colleagues used a gastrocnemius fatigue model in military recruits (136). 
Participants completed a 2-km run and 30-km desert march separately, with 
gastrocnemius fatigue and tibial compression strain rates being measured post-exercise.  
Results suggested the fatigued state increases bone strains and may be a major factor in 
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the origins of tibial stress fractures in this population.  Additionally, in endurance 
sports, even early stages of muscle fatigue have been shown to affect the total bone 
load, specifically the strain rate (137, 138).  Not only muscle strength but limb length 
may be a contributing factor to altered load attenuation.  Conflicting studies argue that 
discrepancies in leg length increase the risk for stress fractures in both military and 
athletic populations (17, 28, 139-141).  It has been hypothesized that the longer the 
bone, the greater the magnitude of the bending moment caused by both tensile and 
compressive forces; however, studies show the fractures do not seem to occur 
preferentially in either the longer or the short leg (8).  To mitigate possible injury, 
manufacturers have turned to a variety of footwear options to reduce the vGRFs the 
lower body must endure during activity. Six randomized controlled trials have evaluated 
the effect of custom insoles on the prevention of stress fractures in military populations 
(142-148).  Results suggest the use of the insoles may reduce the number of stress 
fractures by over 50% (149).   
A bone’s ability to resist injury is predicated on two properties; structural 
stiffness and toughness.  Structural stiffness is determined by the bone’s material 
properties and structural toughness is determined by the spatial distribution or geometry 
of the mineralized matrix.  These properties in relation to the origin and direction of the 
applied load will dictate the risk for bone injury (150).  Under normal circumstances, 
microdamage from mechanical loading stimulates bone formation.  Unfortunately, with 
overtraining, the bone is subjected to increased loading with inadequate rest periods, 
resulting in accelerated and imbalanced remodeling where resorption will become more 
prevalent than formation leading to decreased structural integrity (4, 151). These 
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overuse injuries, often also referred to as stress fractures, frequently occur in lower limb 
bones, especially the tibia, and are highest on the subperiosteal surface (152).  In elite 
military training programs, exercise conditions are relatively uniform between recruits; 
however, fracture rates are not.  Females and smaller recruits tend to report more stress 
fractures, which may suggest a difference in either biomechanical or bone geometry that 
results in the increased risk (19).  Studies on Israeli Army recruits showed that  
participants with fractures had more narrow tibiae and smaller tibial mediolateral cross-
sectional moments of inertia (CSMI) (15, 153).  Beck et al. (19), also found that, 
independent of body size, those who suffered stress fractures were more likely to have 
smaller section moduli in the femur and tibia. 
Bone Status Assessment Techniques 
 
The first documented attempts at quantifying aBMD were in the late 1800’s 
from dental radiographs (154).  The importance of this field quickly grew and by the 
late 1980’s Hologic released their DXA technology.  DXA uses the basic principle of 
X-ray attenuation to measure tissues.  In general, X-rays high and low photon energies 
are passed through the participant and the attenuation of those two energies is measured 
by a detector.  Tissue thickness, density, and composition will alter the attenuation 
profile of each energy beam, which is then used to characterize that tissue in a 2D 
planar image (155).  DXA has now become the gold standard for measuring aBMD 
because of excellent accuracy and precision values paired with low radiation exposures 
for participants (156, 157). Today, DXA machines have a wide range of capabilities that 
include total body and site-specific tissue composition quantification, such as bone 
mineral content and density, fat mass, bone free lean body mass, hip structural analysis, 
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abdominal aortic calcification and trabecular bone score measurements (158-160).  
These measures can be further used to diagnose osteoporosis, fracture risk, and monitor 
changes in body composition and aBMD over time (157, 161).  For aBMD measures, T-
Scores and Z-Scores are also reported on the DXA output, which can be used to define 
low bone mass, osteopenia, and osteoporosis.  For individuals under the age of 50 years, 
a Z-Score will report the number of standard deviations a participant’s aBMD is above 
or below what is normally expected for an age, sex, body mass, and ethnicity matched 
participant.  Scores that are above -2.0 are considered normal, while scores that are 
below -2.0 are considered low bone mass (65).  For individuals over the age of 50 years, 
a T-Score reports the number standard deviations a participant’s aBMD is above or 
below what is normally expected for a Caucasian, female aged between 20-29 years old 
(65). Scores that are -1.0 and above are considered normal, while scores that range from 
-1.1 to -2.4 are defined as having osteopenia, and ≤-2.5 is defined as having 
osteoporosis (65). Bone tissue mineralization and distribution are independent 
predictors of bone strength, and the combination of both of these properties improves 
the estimation of bone strength and fracture risk (162).  As mentioned previously, DXA 
can be used to provide the extent of mineralization; however, the distribution or 
geometry of this tissue is better captured using volumetric measures such as pQCT 
(163, 164).  Much like DXA, pQCT technologies had many precursors that began 
around the late 1960’s and early 1970’s.  This imaging technique quickly began to 
evolve and by the early 1990’s, QCT scanners were being used to image the lumbar 
spine and hips and a peripheral QCT had been developed to assess the appendicular 
skeleton (165, 166).  The pQCT uses the same general concept of X-ray beam 
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attenuation as the DXA.  However, the source and the detector can simultaneously 
rotate around a 180° axis to generate a 3D, volumetric measure instead of a 2D planar 
measure.  pQCT allows researchers to scan nearly any segment of the appendicular 
skeleton and yield bone quality and muscle cross-sectional area results without 
exposing the participant to large radiation doses.  Measures of vBMD, content, area, 
circumferences and a series of bone strength indices provide information about skeletal 
geometry.  The type of bone is very important for understanding fracture risk, as 
cortical and trabecular bone play different roles in bone strength and quality and can be 
differentiated by pQCT (167).  DXA and pQCT are valuable skeletal assessment tools 
separately, as they provide different types of information about the bone tissue; 
however, when used in conjunction, they provide a more complete understanding of 
tissue density, content, geometry and quality. 
Bone Turnover Markers (BTM) are circulating biomarkers that allow 
researchers to make inferences about the real-time skeletal response to stimuli such as 
loading or unloading (20).  BTM have been identified for both resorption and formation 
and can be assayed from small samples of blood or urine.  For example, biomarkers 
such as serum procollagen type I N propeptide (PINP), bone alkaline phosphatase (bone 
ALP), osteocalcin (OC) are commonly used as markers for bone formation, while N or 
C-terminal telopeptide of type I collage (NTX-I or CTX-I), tartrate-resistant acid 
phosphatase (TRAP family) are commonly used to describe bone resorption (21).  
Specifically, PINP and CTX-I are bone turnover markers recommended by the 
International Osteoporosis Foundation (168). 
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In general, the three previously mentioned bone formation markers are 
expressed due to osteoblast activity.  OC is a binding protein exclusively synthesized by 
osteoblasts that aids in the early organization of the matrix as it has specific binding 
sites for calcium (169).  Unfortunately, OC is not protected from rapid degradation in 
serum, so assays have been developed to quantify both the OC fragments and fully 
intact OC molecules (20).  Bone-ALP is an enzyme that aids osteoid formation and 
mineralization (20).  In serum, nearly half of all alkaline phosphatase is from the liver, 
with the other half coming from bone.  Assays used in skeletal research only quantify 
the bone-derived isoforms.  PINP, the last bone formation marker, is in a class of 
peptides that is specific to proliferating osteoblasts (22).  It has very low individual 
variability and is not subject to large changes due to the circadian rhythm (22). 
Bone resorption markers are associated with a variety of cells.  Tartrate-resistant 
acid phosphatase has six isoenzymes that are found in many tissues; however, TRAP5b 
is specific to bone osteoclasts.  TRAP5b is secreted from the osteoclasts' ruffled edge 
during migration from one resorption pit to another and is used as a marker of mature 
osteoclast number and bone resorption activity (25, 170).  When osteoclasts resorb 
bone, a variety of proteins are released; however, 90% of these fragments are type I 
collagen.  NTX-I and CTX-I refer to a terminal collagen crosslink that is either on the 
carboxyl or amino end of the type I collagen.  Both NTX-I and CTX-I provide evidence 
for osteoclast activity and bone resorption; however, CTX-I is more commonly used as 
it has more stable resting values as compared to NTX-I and has now consistently been 
strongly correlated with changes in BMD (24).   
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 BTM have been shown to be strong predictors of stress fracture risk in clinical 
populations (26, 27).  However, the evidence for BTM correlation to stress fracture is 
inconsistent within military groups.  Prospective studies have found that BTM were 
strong predictors of injury status (30), while other studies demonstrated no relationship 
at all in military (3, 17, 31).  New biomarkers, such as PTH and sclerostin need to be 
investigated as potential correlates of injury in military populations.  
Parathyroid hormone (PTH) is responsible for the maintenance of serum calcium 
concentrations needed for normal bone health, muscle function, and many other 
processes.  PTH has multiple mechanisms by which it can mobilize calcium: promoting 
bone resorption, reducing urinary calcium excretion, while simultaneously increasing 
phosphate excretion, and by increasing calcium absorption from the small intestines 
indirectly, and by activating Vitamin D.  In general, PTH and calcium have an inverse 
relationship; short term increases in calcium levels will reduce the release of stored 
PTH from secretory vesicles and trigger the degradation of PTH into fragments (171). If 
serum calcium levels are consistently low, PTH levels will remain elevated.  
Chronically depressed or elevated PTH concentrations, as seen with hypo- and 
hyperthyroidism, can be detrimental to skeletal health; however, intermittent PTH 
administration has been shown to have anabolic effects on bone (172, 173).   
PTH responses to acute and chronic exercise are inconsistent.  Scott et al. (174) 
demonstrated that PTH increased with a single bout of treadmill running in healthy 
males.  Furthermore, they speculated that the increases in PTH concentrations after 
participants reached a workload of 75% VO2 max is due to decreases in serum calcium 
concentrations (174).  Sherk et al. (175) investigated the PTH response to a single bout 
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of cycling, with and without calcium supplementation, to test this idea.  They 
hypothesized that a 1,000 mg calcium chewable supplement taken 30 min prior to the 
cycling bout would protect PTH levels; however, there was no significant difference in 
post-exercise PTH responses between those subjects who received the supplement and 
those who received the placebo (175). However, an acute bout of vigorous walking in 
postmenopausal women revealed that calcium supplementation before and during the 
bout did protect PTH responses (176). PTH responses to chronic exercise have also 
been inconsistent.  Lester et al. (6) investigated exercise mode over eight weeks in 
women who reported fewer than two days per week of PA.  Regardless of exercise 
mode, all groups demonstrated an increase in PTH from pre- to mid-training; however, 
these serum PTH concentrations returned back to pre-training levels by the end of the 
eight week training intervention (6).  High serum PTH levels have been found to be 
associated with stress fracture in military recruits (17, 34); however, contrary findings 
have been observed in athletic and military populations (31, 35, 177-179).   
The Wnt/β-catenin signaling pathway has clearly been characterized as an 
osteogenic process that is tightly regulated. Wnt proteins are a family of secreted 
proteins that can bind to a 7-transmembrane frizzled receptor and low-density 
lipoprotein receptor protein 5 and 6 (LRP5/6).  Once this binding occurs, signals are 
generated, in part due to Disheveled, Axin, and Frat-1, that will inhibit GSK3's ability to 
destabilize β-catenin.  This stabilized β-catenin will translocate to the nucleus, where it 
interacts with T cell factor lymphoid enhancer binding factor (TCF/LEF) to increase 
transcription of proteins and lead to downstream osteogenesis (180). Wnt/β-catenin 
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signaling can be inhibited by an interaction with the LRP5/6 receptor and sclerostin; 
resulting in decreased osteoblast differentiation (37).  
Mechanical loading and hormones such as PTH, calcitonin and glucorticoids can 
reduce sclerostin production (181).  Animal research has demonstrated that deletion of 
the SOST gene or sclerostin KO models have significantly greater bone formation and 
strength as compared to wild type mice (182), and mechanical loading will reduce the 
amount of sclerostin produced by the osteocytes (39).  In humans, sclerostin responses 
are less consistent.  Many cross-sectional studies in adolescent and adult athletic 
populations have shown sclerostin to be increased as compared to less active controls or 
increased after an acute exercise bout.  Falk et al. (38) compared sclerostin responses to 
exercise in boys and men and found that boys had greater resting values of the protein, 
but men had a significantly greater increase in sclerostin post-exercise (38).  Women 
who reported low levels of PA, slowly jogged on a treadmill for 45 minutes, which 
resulted in a nearly 45% increase in serum sclerostin levels (183).  Adolescents who 
were involved in athletics had higher sclerostin concentrations than matched non-
athletes (184), rugby and endurance sport athletes (185) and soccer players (181) all had 
greater sclerostin as compared to matched controls.  However, most of these cross-
sectional studies did not account for plasma volume shifts during the acute exercise 
bout, which could result in the overestimation of sclerostin production.  Many of these 
studies only collected pre/post exercise bout blood samples, which might only 
characterize the brief catabolic state of the bone immediately post-exercise (176).   
In postmenopausal women followed over a five year period, sclerostin was a 
significant positive predictor of fracture (43). Unfortunately, only a few studies have 
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assessed the effects of PA on sclerostin in humans over time. Sclerostin was shown to 
increase during a nine day stage race in nine professional cyclists (186).  Nine 
participants completed a 246-km ultra-distance race and had blood serum samples 
collected before, during, and after participation. The average race time was just over 34 
hours for the nine participants.  Serum sclerostin levels were not different from pre- to 
post-blood draws but were significantly reduced by the third day after the race (41).  
Both of these studies represent such intensive bouts of PA, over short durations of time, 
which make the generalizability of the results difficult.  The only longitudinal 
intervention assessing sclerostin concentrations and PA was a 12-month exercise 
intervention in males with low spine or hip aBMD.  Participants either engaged in 
resistance training or high-intensity jump training, two or three times per week, 
respectively.  Both training programs were periodized and progressive.  Serum 
sclerostin levels were reduced while aBMD increased in both groups (42). 
Exercise Interventions in Military Populations 
As previously mentioned, both drug and exercise interventions have been 
prescribed to cohorts at risk for bone injury, including military personnel.  In 2004, 
Milgrom et al. (187) hypothesized that acute suppression of bone turnover using 
bisphosphonates would decrease the incidence rate of stress fractures in 324 new male 
infantry recruits.  Participants received either a placebo or bisphosphonate risedronate 
during the initial stages of training. A weekly maintenance dose was also administered 
for the duration of the study.  The researchers found no significant reduction in fracture 
risk over the training period (187).   
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Many risk factors for bone injury and fracture can be positively influenced by 
regular physical activity, so it seems more logical to rely on an intervention of this type 
to maximize skeletal benefits.  However, in certain populations, improper prescriptions 
of exercise and rest periods can result in additional bone injuries.  The military has 
completed a variety of studies on the most efficient types of exercise regimens to 
increase strength, power, endurance, and operation specific skills while simultaneously 
reducing the risk for musculoskeletal injuries in their tactical athletes.  Throughout the 
1990s, the Defense Women’s Health Research Program began investigating different 
training protocols specifically to facilitate a better transition for female military recruits. 
The first of three studies was conducted by Knapik, et al. (188).  Thirteen female 
recruits participated in a 14-week training program that consisted of  three days/week  
of resistance training (RT) and two days/week cardiorespiratory training (AT).  Testing 
variables included strength, body composition, and manual material handling (MMH) 
lifting tasks.  Knapik reported 9% decreases in fat mass, 6% increases in lean mass and 
a 16-19% increase in the MMH tasks.  A second study conducted by Harman et al. 
(189) employed a more extensive functional testing program which included higher 
training volume, and a periodized model of resistance training including load carriage, 
plyometrics, interval training and more mission specific tasks, 5 days/week (189).  
Participants increased their 1 repetition maximum (1RM) by 30-47%, repetitive lifting 
capacity by 18-32%, load carriage ability by 24%, aerobic capacity by 14%, and 
decreased reported musculoskeletal injury.  The third study by Kraemer et al. (190) 
followed 83 college-aged women and 100 untrained male controls over a three year 
period where six different, six month training programs were implemented.  All 
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programs were conducted 3 days/week.  Participants either engaged in AT or RT only, 
or the combination of the two. These combination protocols were divided by power and 
hypertrophy repetition ranges and upper and lower body.  Outcome measures included a 
large battery of neuromuscular tests, muscle cross-sectional area via MRI, functional 
tests of a 1RM box lift and repetitive box lifting tasks, plus a 2-mile 75-lb load carriage 
walk.  The primary findings revealed that programs using power repetition ranges, 
resulted in the greatest attenuation of the sex physical performance gap.  This study 
might also provide evidence that untrained women need at least six months, and maybe 
more, as a training plateau was not observed for power and strength (190).  
Subsequently, the Army began updating their training protocols in the early 2000s (50).   
In 2010, the U.S. Army launched the Soldier Athlete Initiative, charged with 
improving physical performance among entry level recruits by changing training tactics 
from traditional push-ups, sit-ups and endurance runs to more strength, power, agility, 
and core training in addition to updated nutrition and injury prevention strategies (7, 
191).  The National Strength and Conditioning Association's Second Blue Ribbon Panel 
of Military Physical Readiness stated strength and power are the two most important 
aspects of successful completion of military tasks while reducing injury rates (192).  
Part of the training doctrine changes implemented in the early 2000s included the 
reduction of long distance running and the inclusion of more high intensity interval 
training (HIIT).  HIIT has been shown to have positive biochemical effects in as short 
as two weeks (177, 193).  Burgomaster et al., (193) demonstrated that over six sessions 
in two weeks (only 15 minutes of total exercise time) there were significant increases in 
citrate synthase (38%), resting muscle glycogen (26%) and cycle endurance capacity 
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(100%).  Later work also highlighted a significant increase in the maximal activity of 
cytochrome c oxidase (COX) and COX II, suggesting greater electron transport chain 
capacity (194).  Gibala et al.’s research protocol required only 2.5 hours of interval 
training as compared to the endurance training group that worked 10.5 hours (194).  
HIIT provides great potential for positive mitochondrial adaptations in shorter periods 
of time as compared to traditional AT training.  One concern is that concurrent AT more 
than four times per week above 80% VO2 max has been shown to override positive 
neuromuscular adaptations to strength and power gains from RT (195).  This has been 
termed the interference effect.  Hendrickson et al. (196) demonstrated a minor 
interference effect in female military recruits; however, the concurrent AT and RT still 
resulted in an increase in all occupational task scores as compared to AT or RT alone. 
Summary 
 Uncoupled and dysfunctional signaling of bone cells may result in low BMD, 
which can increase the risk of fracture or bone injury.  Many factors are implicated in 
this process; however, only a few are controllable.  Dietary, pharmaceutical, and 
exercise interventions have demonstrated attenuation of bone loss in a variety of 
populations, including military cohorts.  The occupational demands of military 
personnel are unusual and can result in overuse musculoskeletal injuries; however, the 
exact relationships between aerobic fitness, strength, power, and skeletal metabolism 
are not well characterized.  New assessments are needed to better understand what 






Chapter 3: Methodology 
 
The purpose of this study was to assess the effects of an eight week MTIP, on 
changes in PTH and sclerostin serum concentrations, and aBMD of the total body, dual 
femur, and lumbar spine, and bone geometry of the non-dominant tibia in healthy, 
college-aged, Marine Corps. and Naval ROTC members compared to a matched control 
group.  Additionally, the relationship between these biomarkers and parameters of bone 
health were examined.  Lastly, body composition, upper and lower body muscular 
strength and power measures and aerobic fitness were compared between groups and 
the correlation between biomarkers and bone parameters was determined. 
Participants 
In total, 42 participants (ROTC members, n=20; controls, n=22), were enrolled 
in the study; however, due to attrition only 36 participants were included in the analysis 
(ROTC members, n=18; controls, n=18).  Eight females (ROTC members, n=4; 
controls, n=4); 4 of which reported using oral contraceptives while 1 female reported 
using a Nexpalnon implant. 31 participants (ROTC members, n=16; controls, n=15) 
who completed pilot testing during the fall semester (IRB#8338) were again recruited 
for participation in the current study. Other OU ROTC participants were recruited after 
the OU Naval ROTC commanding officer, Captain Lyle Hall, granted permission 
(Appendix B).  Captain Hall and the OU Naval ROTC program oversee both USMC 
and Naval ROTC students and organized group meetings for recruitment opportunities.  
All control participants were recruited from the University of Oklahoma using word of 
mouth and fliers. Participants were informed of the risks and benefits before providing 
written consent prior to testing.  All procedures were approved by the Institutional 
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Review Board at the University of Oklahoma Health Sciences Center (OUHSC IRB # 
8600). 
Experimental Group Inclusion Factors 
1. Participants were males and females between 18-30 years old. 
2. Participants were active members of either the Marine Corps or Naval OU 
ROTC programs. 
3. Participants were healthy and free of any diseases or disorders known to  
impair skeletal health or limit their ability to perform vigorous exercise such 
as osteoporosis, cardiovascular disease, or uncontrolled hypertension. 
4. Women were screened for having regular menstrual cycles, defined as not 
having more than three consecutive months without a period. Women who 
reported using hormonal contraceptives were not excluded. 
5. Body weight was less than 300 lbs (136.3 kg), and height was less than 76 in  
(1.92 m) which are the limits of the DXA machine. 
Experimental Group Exclusion Factors 
 
1. Women who were pregnant or planning on becoming pregnant. 
2. Individuals who had a history of taking medications known  
to affect BMD, such as glucocorticoids, bisphosphonates, and calcitonin. 
3. Individuals who had metal implants in the spine, hips or legs. 
4. Individual who were current smokers or who had smoked within six months. 
Control Group Inclusion Factors 
1. Participants were sex, age (±2yrs), and body mass (±2.3kg) matched to a 
ROTC member participant. 
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2. Participants engaged in physically activity at least three times per week. 
3. Participants were healthy and free of any diseases or disorders known to  
impair skeletal health or limit their ability to perform vigorous exercise such 
as osteoporosis, cardiovascular disease, or uncontrolled hypertension. 
4. Women had regular menstrual cycles, defined as not having more than  
three consecutive months without a period. 
5. Body weight was less than 300 lbs (136.3 kg), and height was less than 76 in  
(1.92 m) which are the limits of the DXA machine. 
Control Group Exclusion Factors 
1.  Women who were pregnant or planning on becoming pregnant. 
2.  Individuals who had a history of taking medications known to affect BMD,   
such as glucocorticoids, bisphosphonates, and calcitonin. 
3.  Individuals who had metal implants in the spine, hips or legs. 
Research Design 
This was a mixed factorial research design with one within-subjects variable 
(time) and one between subjects variable (group).  Pre and post an eight week MTIP 
blood draws were used to determine changes in PTH and sclerostin serum 
concentrations, and aBMD of the total body, dual femur, and lumbar spine, and bone 
geometry of the non-dominant tibia in healthy, college aged, Marine Corps and Naval 
ROTC members as compared to a matched control group.  Additionally, the relationship 
between these biomarkers and parameters of bone health were examined.  Lastly, body 
composition, upper and lower body muscular strength and power measures and aerobic 
fitness were compared between groups and the correlation to biomarkers was 
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determined.  The eight week MTIP during the Spring of 2018, had three time points of 
data collection in January (pre), March (mid) and April (post) as shown in Figure 1.  All 
visits took place in the Bone Density Research Laboratory and the Neuromuscular 
Performance Laboratory.  
 
Figure 1. Overview of the Recruitment Process and Research Design. 
 
For the first visit, participants completed the consent process and filled out a 
series of questionnaires including a Health Status Questionnaire, a Physical Activity 
Readiness Questionnaire (PARQ), a Menstrual History Questionnaire, a Calcium Intake 
Food Frequency Form, training logs and a Bone Specific Physical Activity 
Questionnaire (BPAQ).  Participants also became familiar with the methods required for 
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using a hand grip dynamometer, jump performance testing, bench press, leg press, and 
the maximal graded exercise treadmill test. The individuals who qualified for the study 
based on pre-screening were scheduled for the second visit. The second visit consisted 
of a blood draw, urine sample, bone scans, and physical performance testing. The serum 
was used to quantify the biomarkers, PTH and sclerostin. The urine sample was used to 
check hydration values and female pregnancy status. Four DXA scans (total body, 
lumbar spine, dual proximal femur) and three pQCT scans (4%, 38%, 66% length of the 
non-dominant tibia) followed the blood draw. Also, body composition variables (total 
and regional percent body fat (%BF), FM, BFLBM) were obtained from the total body 
DXA scan.  Upper body strength testing involved grip strength and a 1 repetition 
maximum (1RM) bench press.  Lower body strength testing included a jump 
performance test and a 1RM leg press.  Lastly, the third visit consisted of a modified 
Balke graded exercise treadmill protocol that was used to measure peak VO2 
(mL/kg/min). 
Questionnaires 
 All participants completed several forms of paperwork and questionnaires 
during the first visit.  The following items provided researchers screening information 
and also important classification data. 
1. Informed Consent and HIPAA - these forms were used to ensure the participant 
had a complete understanding of the study procedures including potential risks 
and benefits. 
45 
2. Health Status Questionnaire - is an in-house questionnaire used to provide 
additional screening information to ensure the participant was qualified for the 
study and it was safe for them to participate. 
3. Training Questionnaire - this form was used to describe auxiliary forms of PA in 
which the participants were engaging in outside of the intervention and any 
musculoskeletal injuries they may have sustained during this time, such as shin 
splints or stress fractures. 
4. Bone-Specific Physical Activity Questionnaire (BPAQ) – was used to quantify 
bone loading activities that participants were engaged in.  Total, past, and current 
BPAQ scores were calculated (197). 
5. Physical Activity Readiness Questionnaire (PARQ) – was used to see if  
 participants could begin a physical activity program, by screening for diseases. 
6. Calcium Intake - was assessed before the MTIP began, using a calcium-rich 
foods frequency questionnaire (198). 
7. Menstrual History - an in-house menstrual history questionnaire was used to  
 describe female participant menstrual cycle characteristics over the past 12   
months and contraceptive use, age at menarche, symptoms of menstrual cycle 
and hormonal disturbances.                                                                                                                        
Anthropometric Measures 
 Body mass and height were measured using a Tanita BWB-800 digital scale 





For measuring hydration and pregnancy status in females, the participants 
provided a small urine sample.  To measure hydration, a VEE GEE-CLX-1 
refractometer (VEE GEE Scientific Inc, Kirkland, WA) was used to measure urine 
specific gravity.  All participants were reminded to come to the lab hydrated and ready 
to provide a urine sample.  Samples had to be within 1.004-1.029 in order to undergo a 
DXA scan.  If participants were dehydrated, they were given water and retested after 30 
minutes, if participants were over-hydrated they were asked to reschedule the visit.  
Female participant urine samples were also used to test for pregnancy using a 
pregnancy strip (SA Scientific, San Antonio, TX).  The urine sample was allowed to 
reach room temperature and the pregnancy strip was dipped into the urine for 15 
seconds and then left to rest for four minutes, after which time the strip was read. 
Dual Energy X-ray Absorptiometry 
DXA (GE Lunar Prodigy, enCORE software, version 13.31.016, GE Healthcare, 
Madison, WI) was used to measure whole body composition and aBMD. Measures of 
total FM (g), %BF, BFLBM (g), and bone mineral content (BMC) (g) were obtained 
from the whole body scan. aBMD is measured using specific scans of the total body, 
lumbar spine (L1-L4), and dual proximal femur (total hip, femoral neck, trochanter).  
For the total body scan, participants were asked to lie on the DXA table in the supine 
position, centered within the scan field.  The hands were placed on the sides of the legs, 
in the prone position, while the legs were straight and strapped together. Participants 
remained centered and placed their legs on a foam block so the lumbar spine was 
completely flat for the lumbar spine scan.  Lastly, for both proximal femur scans, the 
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feet were strapped to an angled brace to create internal rotation of the femur.  In the 
Bone Density Research Laboratory, the root mean square coefficient of variation (RMS 
CV %) for body composition variables for Total FM, BFLBM and %BF are 2.74%, 
1.39%, and 2.5%, respectively.  The in vivo RMS CV % for the aBMD of total body is 
0.6%, L1-L4 is 0.9% and 0.4-0.8% for the proximal femur sites. The same trained 
technician conducted all scans. 
Peripheral Quantitative Computed Tomography 
 A pQCT scanner (XCT 3000, Software v.6.00, Stratec Medizintechnik GmbH, 
Pforzheim, Germany) was used to measure tibia bone geometry characteristics and 
muscle cross-sectional area (mCSA).  Tibia length of the non-dominant limb was 
measured from the medial malleolus to the tibial plateau. Leg dominance was defined as 
the participant’s self-reported preferred kicking leg.  Participants were seated with their 
leg supported horizontally and centered in the gantry.  Tibia scans were obtained at 4%, 
38%, and 66% of tibia length proximal to the reference line. A voxel size of 0.4 mm 
was used for all sites at the scout view speed of 40 mm/sec and CT speed of 20 mm/sec.  
At the distal tibia (4%), contour mode 3 at 169 mg/cm3 and peel mode 4 at 650 mg/cm3 
with a 10% peel were used to determine total vBMD (mg/cm3), total bone area (mm2), 
trabecular vBMD (mg/cm3 ), and trabecular area (mm2).  For the 38% and 66% tibia 
sites, cort mode 2 at 710 mg/cm3 was used to define total vBMD (mg/cm3), total bone 
area (mm2), cortical density (mg/cm3), cortical area (mm2), and cortical thickness (mm), 
while cort mode 2 at 480 mg/cm3 was used to obtain torsional strength for strength-
strain index (SSI) (mm3).  In the Bone Density Research Laboratory, the RMS CV% for 
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the pQCT bone measurements ranges from 0.31-1.21% for all sites. The same trained 
technician who performed all DXA scans also conducted all pQCT scans and analysis. 
Muscular Strength and Power Measures 
All participants completed two upper and two lower body specific tests of 
strength and power.  Lower body muscle power was assessed by a maximum counter 
movement jump (CMJ).  Using a validated jump mat (Just Jump, Probotic, AL) with a 
Tendo FiTRODYNE power and speed analyzer (Tendo Sports Machines, Trencin, 
Slovakia), participants jump power (w), velocity (m/s), time in the air (s) and vertical 
jump (cm) was recorded.  Participants were instructed to squat down to a self-selected 
depth and then use a forceful arm swing to jump as high as possible.  Each participant 
jumped three times with a one-minute rest between trials.  The Bone Density Research 
Laboratory Intraclass Correlations (ICC) values for jump power, velocity, air time, 
jump height range between 0.80-0.98.  Additionally, lower body strength was 
determined using a decline leg press machine (Body Solid, Forest Park, IL).  An eight 
trial 1RM protocol was used, per National Strength and Conditioning Association 
recommendations (199).  The same 1RM protocol was used for the upper body strength 
assessment using bench press (Cybex, Medway, MA).  The Neuromuscular Laboratory 
ICCs for leg press and bench press 1RM testing are 0.997 and 0.999, respectively (200).  
Lastly, grip strength was measured using the Jamar handgrip dynamometer (Patterson 
Medical, IL) (201). The ICC for this handgrip dynamometer in the Bone Density 




Graded Exercise Treadmill Testing          
Maximal aerobic capacity was measured using a modified Balke treadmill 
protocol with open-circuit spirometry (ParvoMedics; Sandy, UT).  Participants warmed 
up to determine the jogging speed that elicited a heart rate equivalent to 75% of age-
predicted maximal heart rate.  This speed was maintained or increased while the 
treadmill grade was increased by 2% every 2 minutes.  Heart rate was monitored 
continuously using a coded transmitter worn around the chest (Polar T31, Bethpage, 
NY).  Prior to the end of each stage, participants were asked their Rating of Perceived 
Exertion (RPE) (202).  VO2 peak was calculated as the average of the two highest 
consecutive 30-second VO2 measurements (176).   
Four criteria were used to identify maximal oxygen uptake; a plateau in oxygen 
consumption despite an increased workload, RER values over 1.10, RPE values 18 or 
over, and maximal HR within 10 bpm of the age predicted max HR.  Average RER was 
1.14, average max heart rate was 196bpm, and average RPE was 18.7.  After visual 
inspection of VO2 kinetics, 56 of the 64 exercise tests demonstrated a clear plateau in 
oxygen consumption.  Of the eight tests that were not clear six tests reached all of the 
other criteria for max.   
Exercise Intervention 
OU ROTC participants completed the same biweekly, eight week structured 
training programs within each branch.  All USMC OU ROTC members completed the 
same frequency, time, and type of exercises; however, the intensity for each exercise 
could have been different for each participant based on ability and effort.  Navy OU 
ROTC members also completed the same frequency, time, and type of exercises; 
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however, these were not always the same as the USMC OU ROTC members.  The 
Spring 2018 MTIP began January 29th and ended April 5th.  Exercises conducted by 
both branches could be categorized as body weight work, resistance training, or 
endurance training.  For instance, in one day OU ROTC members might have        
completed 100 push-ups, 100 sit-ups (body weight work), followed by a 3-mile run 
(endurance), 3x5 leg press (resistance training).  Each exercise incorporated different 
aspects of all three types of exercises.  Figure 2 shows an example of a USMC OU 
ROTC circuit that includes both body weight work and resistance training components.  
Figure 2. USMC OU ROTC Sample Circuit Workout. 
Blood Sampling and Biomarker Assays 
Participants were instructed to refrain from PA 24 hours prior, and be at least 
eight hours fasted for all blood draws.  Blood samples (approximately 10mL) were 
collected via venipuncture by a certified phlebotomist at Goddard Health Center or in 
the Bone Density Research Laboratory in the morning (8:00-9:00am).  Each sample was 
allowed to clot, then centrifuged to separate the serum from the red blood cells.  The 
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serum was aliquoted into microtubes, labeled, and stored in a -84°C freezer located in 
the Bone Density Research Laboratory until assays were performed.  Prior to each 
assay, the frozen serum samples and all kit components were allowed to reach room 
temperature.  All samples were assayed in duplicate.  The immunoassay kit used for the 
quantification of PTH was from DRG International Inc., Springfield, NJ. (Cat# 
EIA3645).  Intra-assay CV% ranged from 0.3- 7.7% and inter-assay CV% was 8.0% for 
the low control and 8.5% for the high control. The immunoassay kits from TECO 
medical Quidel Corp., Santa Clara, CA and Sissach, Switzerland (Cat# TE1023-HS) 
were used to measure sclerostin serum concentration levels.  Intra-assay CV% ranged 
from 0.2-9.4% and inter-assay CV% was 20.1% for the low control and 4.7% for the 
high control.  Instructions for each assay kit (Appendix F) were followed as were all 
standard precautions for Biosafety level 2. 
Statistical Analysis 
All statistical procedures were performed using IBM SPSS (v23, Armonk, New 
York), and significance was set at p≤0.05.  Data was tested for normality using the 
Kolmogorov-Smirnov test and reported as means ± standard deviation (SD) in tables 
and means ± standard error (SE) in figures.  A Mann-Whitney U test was used to 
analyze baseline differences in calcium intake between groups while Friedman tests 
were used to detect group and time differences in left hand grip strength as these two 
variables were not normally distributed.  For normally distributed variables, group 
(ROTC and control) differences in physical characteristics were examined using 
independent t-tests.  No significant differences for age, body mass, or height were found 
so no covariates were used in subsequent analyses. For variables only measured at the 
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beginning and end of the intervention period, two-way repeated measures ANOVA was 
used to determine group (ROTC, control) and time (pre, post) main effects and group × 
time interactions.  If there was a significant interaction effect, the model was 
decomposed using paired t-tests for pre and post variables within each group.  These 
variables included both biomarkers, lumbar spine and dual femur DXA scans, all pQCT 
measures, and aerobic capacity variables.  For variables which also included a midway 
testing period, two-way repeated measures ANOVA was used to determine group 
(ROTC, control) and time (pre, mid, post) main effects and group × time interactions.  
If there was a significant interaction effect, the model was decomposed and separate 
one-way repeated measures ANOVAs with Bonferroni post-hoc procedures were 
performed separately for each group. These variables included all measures from total 
body DXA scans, and the muscular strength and power measures of grip strength, jump 
power, bench press, and leg press. Additionally, percent changes were calculated for all 
dependent variables and were analyzed using independent t-tests with a Bonferonni 
correction, the equation used was [(post-pre)/post]*100.  Pearson Product Moment 
correlation coefficients (r) were used to determine relationships between biomarkers, 
bone variables, body composition, and physical performance measures.  Lastly, multiple 
linear regression using the stepwise method was used to identify predictors of total 






Chapter 4: Results and Discussion 
 
The purpose of this study was to determine the effects of an eight week military 
training intervention on PTH and sclerostin serum concentrations, and aBMD of the 
total body, dual femur, and lumbar spine, and bone geometry of the tibia, in healthy, 
college-aged USMC and Naval Reserve Officers’ Training Corps (ROTC) members 
compared to a matched control group. A secondary purpose was to determine the 
relationship between PTH and sclerostin and bone variables. Lastly, group differences 
in body composition, muscular strength and power measures, and aerobic fitness and 
their relationships to PTH and sclerostin were examined.   
Participant Characteristics 
 A total of 42 participants (ROTC n=20, Controls n=22) were enrolled in the 
study.  Three control participants were excluded prior to testing due to voluntary 
termination (n=1), injury (n=1), and an inability to maintain a matching body mass 
(n=1).  Another control participant became injured between the mid and post testing 
periods and was removed.  One ROTC member was excluded prior to testing due to 
severe illness and another due to voluntary termination after the mid testing period. In 
total, 36 participants aged between 18-29 years (ROTC n=18, controls n=18) were 
included in the final analysis.  Of the eight females enrolled, (ROTC members, n=4; 
controls, n=4); 4 reported using oral contraceptives while 1 female reported using a 
Nexpalnon implant. All matching criteria were maintained for the final 36 participants 
with no significant changes in height or body mass occurring over time for either group.  
Hand and foot dominance was determined by asking the participant which hand they 
threw a ball with, and which foot they kicked a ball with.  Four participants reported 
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being left handed while only two reported being left footed. Participants were not 
recruited or matched according to ethnicity though the vast majority of participants self 
identified as Caucasian (n=32); other ethnicities represented were Hispanic (n=2), Black 
(n=1), and Other (n=1).  One control participant reported sustaining a stress fracture due 
to activity unrelated to the study.  No ROTC participants reported any signs or 
symptoms of any bone injuries throughout the eight week intervention period. 
 Baseline participant characteristics are found in Table 1. No significant 
differences existed between groups for age, height, body mass, calcium intake or past, 
current, and total BPAQ scores (all p ≥0.058).  Additionally, no significant group 
differences were found for the total number of days per week of reported physical 
activity (PA), resistance training (RT), or endurance training (ET), this information was 
gathered from the Auxiliary Training Questionnaire (Appendix E). Although not shown 
in Table 1, body mass index (BMI) ranged from 18.9-26.8 kg/m² with only 11 
participants (ROTC n=6; controls n=5) in the overweight category. Calcium intake 
group means were above the recommended 1000 mg/day (203).  
Table 1. Baseline Participant Characteristics (means ± SD). 
  ROTC (n=18) Controls (n=18) 
Age (years) 20.4 ± 2.4 21.2 ± 1.8 
Height (cm) 175.7 ± 9.1 177.5 ± 6.7 
Body Mass (kg) 73.4 ± 10.9 74.5 ± 10.7 
Calcium Intake (mg/day) 1165 ± 571 1072 ± 725 
BPAQ- Past 46.9 ± 27.8 53.2 ± 36.1 
BPAQ- Current 6.2 ± 4.2 6.8 ± 5.5 
BPAQ- Total 26.6 ± 14.6 29.9 ± 19.0 
Days/Week PA 4.9 ± 1.4 4.9 ± 1.0 
Days/Week RT  4.1 ± 1.6 3.5 ± 1.8 
Days/Week ET 3.5 ± 1.7 2.4 ± 1.8 
BPAQ: Bone Physical Activity Questionnaire RT: Resistance Training 
PA: Physical Activity ET: Endurance Training 
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Dual Energy X-ray Absorptiometry Measures 
 DXA was used to assess changes in aBMD and body composition for the total 
body and site specific areas.  Table 2 shows information regarding the three total body 
scans that were completed at the pre, mid, and post testing periods.  No significant 
group × time interactions, or main effects for time or group were found for total body 
aBMD, BMC, or fat mass (all p≥0.083).  Significant time effects were found, total BF% 
decreased while total body BFLBM increased from pre to mid points (both p≤0.050).  
No significant group effects were found for total body aBMD, BMC, BF%, fat mass, or 
BFLBM (all p≥0.165).  All participants had normal aBMD values according to their Z-
Scores per International Society for Clinical Densitometry guidelines (204).   
Table 2. Total Body aBMD and Body Composition Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Total Body aBMD (g/cm2) Pre 1.329 ± 0.112 1.348 ± 0.123 
 Mid 1.326 ± 0.115 1.338 ± 0.119 
 Post 1.314 ± 0.131 1.343 ± 0.116 
Total Body BMC (g) Pre 3023.26 ± 521.22 3020.36 ± 500.37 
 Mid 3028.78 ± 513.70 3022.60 ± 505.41 
 Post 3040.81 ± 519.32 3019.30 ± 492.58 
Total Body % Fat Pre 20.8 ± 5.5 21.8 ± 6.6 
 Mid * 20.3 ± 5.7 21.2 ± 6.2 
 Post 20.4 ± 5.8 21.3 ± 6.2 
Total Body Fat Mass (kg) Pre 15.2 ± 4.2 16.1 ± 4.2 
 Mid 14.8 ± 4.1 15.6 ± 4.1 
 Post 14.9 ± 4.3 15.7 ± 3.9 
Total Body BFLBM (kg) Pre 55.3 ± 9.7 56.5 ± 11.5 
 Mid * 55.9 ± 10.1 57.0 ± 11.7 
 Post 55.8 ± 10.4 56.9 ± 11.8 
aBMD: Areal Bone Mineral Density * Significantly different than Pre p≤0.05 
BMC: Bone Mineral Content     
 
  





Regional aBMD and body composition information is in Table 3.  No significant 
group × time interactions, or main effects for time or group were found for arm BMC, 
leg BMC, or leg BFLBM (all p≥0.309).  A significant time effect was found as arms % 
fat and fat mass significantly decreased from pre to mid testing periods (both p≤0.047).  
Arm BFLBM significantly increased from pre to mid and from pre to post testing 
periods (both p≤0.047).   Legs % fat and fat mass also decreased from pre to mid testing 
periods but returned to baseline values at the post testing period (both p≤0.018).  
Table 3. Regional aBMD and Body Composition Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Arms BMC (g) Pre 434.5 ± 106.1 418.4 ± 99.8  
Mid 435.4 ± 102.2 419.7 ± 98.5  
Post 435.6 ± 107.3 417.0 ± 97.0 
Arms % Fat Pre 18.4 ± 7.0 19.5 ± 7.8  
Mid * 17.9 ± 7.1 18.9 ± 7.3  
Post * 17.9 ± 7.2 18.9 ± 7.4 
Arms Fat Mass (kg) Pre 1.7 ± 0.5 1.7 ± 0.4  
Mid * 1.6 ± 0.5 1.7 ± 0.4  
Post * 1.6 ± 0.5 1.6 ± 0.4 
Arms BFLBM (kg) Pre 7.4 ± 2.0 7.4 ± 2.4  
Mid * 7.5 ± 1.9 7.4 ± 2.4  
Post ‡ 7.5 ± 2.1 7.4 ± 2.4 
Legs BMC (g) Pre 1139.1 ± 218.9 1090.0 ± 223.9  
Mid 1139.1 ± 215.1 1111.0 ± 219.4 
 
Post 1140.1 ± 221.0 1133.7 ± 226.4 
Legs % Fat Pre 23.5 ± 6.5 23.6 ± 8.1  
Mid * 23.0 ± 6.8 22.6 ± 8.1  
Post 22.8 ± 6.5 23.3 ± 7.7 
Legs Fat Mass (kg) Pre 6.0 ± 1.7 6.1 ± 1.6  
Mid * 5.9 ± 1.6 5.8 ± 1.5  
Post 5.9 ± 1.7 5.9 ± 1.4 
Legs BFLBM (kg) Pre 18.7 ± 3.5 18.7 ± 4.6  
Mid 18.9 ± 3.6 20.0 ± 5.8 
  Post 19.0 ± 3.6 19.4 ± 4.5 
BMC: Bone Mineral Content *Significantly different than Pre p≤0.05 
BFLBM: Bone Free Lean Body Mass ‡Significantly different than Mid p≤0.05 
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Lumbar Spine (L1-L4) and dual hip aBMD and BMC variables are displayed in 
Tables 4 and 5.  No significant group × time interactions, or main effects for time or 
group were found for any non-dominant hip variables or dominant trochanter aBMD, 
femoral neck BMC, or trochanter BMC (all p≥0.059).  Significant group × time 
interactions were found for the spine, dominant femoral neck, and dominant total hip 
aBMD and BMC (all p≤0.033).  However, post hoc analysis showed that the spine 
aBMD was not significantly different between time points within these groups (both p ≥ 
0.076).  Dominant femoral neck aBMD significantly increased in ROTC and decreased 
in controls (both p≤0.024). The dominant total hip aBMD significantly increased in 
ROTC, p=0.017; while, dominant total hip BMC significantly decreased in controls, 
p=0.020. Figure 3 shows the significant interaction effect for dominant total hip aBMD.  
Table 4. Lumbar Spine and Dual Hip aBMD (g/cm2) Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Lumbar Spine L1-L4 Pre 1.305 ± 0.110 1.325 ± 0.162  
Post † 1.312 ± 0.117 1.318 ± 0.153 
Dominant        
     Femoral Neck Pre 1.219 ± 0.136 1.244 ± 0.154 
 Post † 1.229 ± 0.143* 1.232 ± 0.154* 
     Trochanter Pre 0.979 ± 0.122 0.963 ± 0.149 
 Post 0.982 ± 0.122 0.954 ± 0.148 
     Total Hip Pre 1.202 ± 0.134 1.200 ± 0.163 
 Post † 1.210 ± 0.132* 1.197 ± 0.163 
Non-Dominant        
     Femoral Neck Pre 1.220 ± 0.137 1.237 ± 0.169 
 Post 1.221 ± 0.137 1.239 ± 0.167 
     Trochanter Pre 0.976 ± 0.122 0.985 ± 0.178 
 Post 0.982 ± 0.123 0.973 ± 0.158 
     Total Hip Pre 1.199 ± 0.134 1.199 ± 0.175 
  Post 1.203 ± 0.130 1.200 ± 0.169 





Table 5. Lumbar Spine and Dual Hip BMC (g) Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Lumbar Spine L1-L4 Pre 75.7 ± 14.0 83.0 ± 18.3  
Post 77.3 ± 12.8 83.2 ± 18.0 
Dominant        
     Femoral Neck Pre 6.3 ± 1.0 6.3 ± 1.1 
 Post 6.3 ± 1.1 6.2 ± 1.1 
     Trochanter Pre 14.1 ± 3.2 12.9 ± 3.8 
 Post 14.2 ± 3.2 12.7 ± 3.9 
     Total Hip Pre 41.4 ± 6.7 40.2 ± 7.8 
 Post † 41.6 ± 6.8 39.8 ± 7.7* 
Non-Dominant        
     Femoral Neck Pre 6.3 ± 1.1 6.3 ± 1.1 
 Post 6.3 ± 1.0 6.3 ± 1.2 
     Trochanter Pre 14.1 ± 2.7 13.3 ± 4.1 
 Post 14.3 ± 2.8 13.4 ± 4.1 
     Total Hip Pre 41.5 ± 6.4 40.6 ± 8.1 
  Post 41.7 ± 6.5 40.6 ± 8.0 
† Significant Group × Time Interaction p≤0.05 *Significantly different than Pre p≤0.05 
Figure 3. Dominant Total Hip aBMD Group Responses Over Time (means ±SE).                       


































No significant group × time interactions, or main effects for time or group were 
found in either the dominant or non-dominant hip strength index, buckling ratio, section 
modulus, or cross-section moment of inertia (all p≥0.180) as shown in Table 6. 
Table 6. Hip Structural Analysis Variables Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Dominant Hip        
     Strength Index  Pre 1.8 ± 0.3 1.6 ± 0.4 
 Post 1.7 ± 0.3 1.7 ± 0.4 
     Buckling Ratio Pre 2.8 ± 1.2 2.8 ± 1.5 
 Post 2.5 ± 0.8 3.0 ± 1.3 
     Section Modulus (mm³) Pre 925.5 ± 228.2 885.4 ± 188.6 
 Post 919.0 ± 248.5 876.0 ± 180.2 
     CSMI (mm⁴) Pre 15550 ± 5441 14116 ± 3998 
 Post 15363 ± 5715 14060 ± 3812 
Non-Dominant Hip        
     Strength Index Pre 1.8 ± 0.3 1.7 ± 0.3 
 Post 1.7 ± 0.3 1.7 ± 0.3 
     Buckling Ratio Pre 2.7 ± 1.4 3.0 ± 1.3 
 Post 2.4 ± 1.0 3.0 ± 1.4 
     Section Modulus (mm³) Pre 905.8 ± 216.8 913.9 ± 214.6 
 Post 906.1 ± 220.6 908.4 ± 198.8 
     CSMI (mm⁴) Pre 15373 ± 5582 14953 ± 4602 
  Post 15569 ± 5350 14918 ± 4704 
CSMI: Cross-Section Moment of Inertia       
 
Peripheral Quantitative Computed Tomography Measures 
Tables 7-9 depict the changes over time in pQCT variables from the 4%, 38%, 
and 66% non-dominant tibia sites.  No significant group × time interactions, or main 
effects for time or group were found for any of the variables at the 4% site (all 
p≥0.158), including total and trabecular BMC, vBMD, area, bone strength index, and 
the periosteal circumference as shown in Table 7.   
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Table 7. 4% Non-Dominant Tibia pQCT Variables Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Total        
     BMC (mg/mm) Pre 395.0 ± 64.9 398.2 ± 74.9 
 Post 394.9 ± 64.8 398.2 ± 74.6 
     vBMD (mg/cm³) Pre 344.333 ± 27.703 357.006 ± 37.258 
 Post 344.806 ± 28.178 355.722 ± 36.898 
     Area (mm²) Pre 1149.44 ± 181.15 1118.84 ± 200.20 
 Post 1147.24 ± 179.62 1123.66 ± 203.71 
     BSI (mg²/mm⁴) Pre 136.6 ± 28.3 143.2 ± 36.4 
 Post 136.8 ± 28.6 142.6 ± 36.1 
Trabecular        
     BMC (mg/mm) Pre 324.4 ± 61.6 314.9 ± 68.8 
 Post 323.5 ± 60.6 315.9 ± 68.6 
     vBMD (mg/cm³) Pre 308.572 ± 27.110 312.572 ± 32.326 
 Post 308.594 ± 26.937 311.728 ± 32.714 
     Area  (mm²) Pre 1051.53 ± 175.80 1008.36 ± 195.50 
 Post 1048.34 ± 173.50 1014.97 ± 198.65 
     BSI (mg²/mm⁴) Pre 100.9 ± 25.1 99.4 ± 29.7 
 Post 100.6 ± 24.8 99.5 ± 29.6 
Periosteal Circ. (mm) Pre 119.8 ± 9.6 118.1 ± 10.5 
  Post 119.7 ± 9.5 118.4 ± 10.7 
BMC: Bone Mineral Content   BSI: Bone Strength Index 
vBMD: Volumetric Bone Mineral Density  Circ: Circumference 
  
No significant group × time interactions, or main effects for time or group were 
found for any of the variables at the 38% site (all p≥0.110), including total and cortical 
BMC, vBMD, area, cortical thickness, periosteal and endosteal circumference, iPolar 





Table 8. 38% Non-Dominant Tibia pQCT Variables Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Total        
     BMC (mg/mm) Pre 396.7 ± 53.1 411.8 ± 67.3 
 Post 398.0 ± 54.0 411.9 ± 67.1 
     vBMD (mg/cm³) Pre 934.744 ± 55.116 945.806 ± 65.410 
 Post 936.000 ± 54.684 945.972 ± 65.365 
     Area (mm²) Pre 425.82 ± 62.19 439.54 ± 88.59 
 Post 426.62 ± 62.94 439.66 ± 88.76 
Cortical        
     BMC (mg/mm) Pre 381.3 ± 49.9 394.7 ± 62.9 
 Post 382.4 ± 50.7 394.7 ± 62.3 
     vBMD (mg/cm³) Pre 1175.994 ± 25.824 1171.267 ± 28.178 
 Post 1176.206 ± 24.908 1171.083 ± 28.691 
     Area  (mm²) Pre 324.73 ± 45.16 338.12 ± 60.10 
 Post 325.56 ± 45.51 338.20 ± 59.40 
     Thickness (mm) Pre 5.99 ± 0.59 6.19 ± 0.69 
 Post 6.00 ± 0.59 6.19 ± 0.66 
Periosteal Circ. (mm) Pre 73.0 ± 5.4 73.9 ± 7.6 
 Post 73.0 ± 5.5 74.0 ± 7.7 
Endosteal Circ. (mm) Pre 35.3 ± 5.0 35.0 ± 7.0 
 Post 35.3 ± 4.9 35.0 ± 7.1 
iPolar (mm⁴) Pre 31230.1 ± 8436.4 33066.9 ± 11996.2 
 Post 31356.3 ± 8405.0 33105.3 ± 12082.0 
SSI (mm³) Pre 1910.8 ± 385.4 2013.1 ± 532.5 
  Post 1911.7 ± 382.5 2024.8 ± 536.8 
BMC: Bone Mineral Content   Circ: Circumference 
vBMD: Volumetric Bone Mineral Density  SSI: Stress Strain Index 
 
No significant group × time interactions, or main effects for time or group were 
found for most variables at the 66% site (all p≥0.213), including total and cortical 
vBMD and area, cortical BMC and thickness, periosteal and endosteal circumference, 
iPolar, and SSI as shown in Table 9. Significant time effects were found for 66% total 
BMC and mCSA which significantly increased from pre to post testing periods (both 
p≤0.018). 
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Table 9. 66% Non-Dominant Tibia pQCT Variables Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Total        
     BMC (mg/mm) Pre 435.3 ± 61.0 450.3 ± 74.0 
 Post * 436.3 ± 61.2  450.9 ± 74.1 
     vBMD (mg/cm³) Pre 714.772 ± 87.558 725.839 ± 68.123 
 Post 698.367 ± 50.828 726.878 ± 67.921 
     Area (mm²) Pre 619.49 ± 118.20 625.93 ± 117.94 
 Post 627.71 ± 97.55 625.82 ± 117.73 
Cortical        
     BMC (mg/mm) Pre 396.5 ± 53.9 407.4 ± 64.6 
 Post 397.1 ± 56.4 408.2 ± 65.1 
     vBMD (mg/cm³) Pre 1136.906 ± 25.431 1136.122 ± 25.080 
 Post 1136.800 ± 21.860 1136.839 ± 26.351 
     Area  (mm²) Pre 349.33 ± 50.44 359.57 ± 62.36 
 Post 349.86 ± 52.38 360.03 ± 62.62 
     Thickness (mm) Pre 4.83 ± 0.52 4.93 ± 0.64 
 Post 4.74 ± 0.53 4.94 ± 0.63 
Periosteal Circ. (mm) Pre 87.8 ± 8.9 88.3 ± 8.6 
 Post 88.6 ± 7.0 88.3 ± 8.5 
Endosteal Circ. (mm) Pre 57.5 ± 9.9 57.3 ± 8.3 
 Post 58.7 ± 6.5 57.2 ± 8.2 
iPolar (mm⁴) Pre 57755.4 ± 17937.8 58221.3 ± 19431.4 
 Post 58624.3 ± 16222.0 58224.2 ± 19350.8 
SSI (mm³) Pre 2904.9 ± 701.7 2994.2 ± 745.3 
 Post 2939.8 ± 621.8 2991.7 ± 750.3 
Muscle CSA (mm²) Pre 7534.3 ± 1038.9 7972.4 ± 1736.1 
  Post * 7734.1 ± 1049.7  8043.4 ± 1789.3 
BMC: Bone Mineral Content   Circ: Circumference 
vBMD: Volumetric Bone Mineral Density  SSI: Stress Strain Index 









Blood samples were allowed to clot, then centrifuged to separate the serum from 
the red blood cells, and frozen until assays were performed.  Microtubes and all kit 
components were allowed to reach room temperature and were then assayed in 
duplicate.  Instructions for the assay kits for PTH and sclerostin were followed exactly.  
PTH had two statistical outliers (greater than two box plots) (ROTC n=1; control n=1) 
and sclerostin had one statistical outlier (ROTC n=1). Exclusion of outliers did not 
change any statistical outcomes so subsequent analysis included outliers.  Table 10 
shows the biomarker responses over time for each group.  No sex differences between 
either biomarker responses or %∆ were found when the whole group was considered, or 
when ROTC and controls were considered separately (all p≥0.138). 
Table 10. Biomarker Responses Over Time (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Parathyroid Hormone (pg/mL) Pre 40.85 ± 22.52 47.77 ± 19.52 
 Post 46.61 ± 22.37 45.78 ± 16.01 
Sclerostin (ng/mL) Pre 0.420 ± 0.137 0.393 ± 0.097 
  Post 0.405 ± 0.122 0.386 ± 0.115 
 
Parathyroid Hormone 
No significant group × time interactions, or main effects for time or group were 
found (all p≥0.323) as shown in Table 10 and Figure 4. Mean PTH percent changes 




                 
Figure 4. Serum Parathyroid Hormone Concentrations (means ± SE). 
 
 
Figure 5. Percent Changes in Parathyroid Hormone Concentrations (means ± 95% CI). 






























Figure 6 displays the changes over time in the serum sclerostin concentrations 
for each group.  No significant group × time interactions, or main effects for time or 
group were found (all p≥0.189) as shown in Table 10.  Mean sclerostin percent changes 
were  -2.7 % and -2.1% in ROTC and controls respectively (p=0.501) as shown in 
Figure 7.      
           
 
























Figure 7. Percent Changes in Sclerostin Concentrations (means ± 95% CI). 
X denotes mean; line denotes median; boxes denote the 75th and 25th quartiles. 
 
Physical Performance Measures 
No significant group × time interactions were found for any of the muscle 
strength and power measures (all p≥0.143); however, significant time effects were 
found as shown in Table 11.  No significant changes occurred in the right hand grip 
strength; however, left hand grip strength decreased significantly at the post testing 
period.  Both jump height and time in the air and bench press and leg press increased 
from pre to mid and leveled off at the post testing period (all p≤0.024).  Jump power 
and velocity increased pre to mid, however, returned to baseline by the post testing 
period (all p≤0.003).  
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Table 11. Muscular Strength and Power Measures Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Right Hand Grip (kg) Pre 48.2 ± 10.6 46.4 ± 10.1 
 Mid 48.2 ± 10.5 47.2 ± 11.6 
 Post 46.6 ± 11.0 45.9 ± 11.0 
Left Hand Grip (kg) Pre 46.3 ± 11.6 46.1 ± 12.1 
 Mid 46.1 ± 10.8 47.5 ± 13.8 
 Post * ‡ 43.8 ± 9.5 45.2 ± 13.5 
Jump Height (cm) Pre 48.5 ± 9.9 51.1 ± 11.5 
 Mid * 50.5 ± 9.1 53.3 ± 12.7 
 Post * 49.5 ± 9.4 52.3 ± 12.7 
Time in Air (sec) Pre 0.62 ± 0.07 0.62 ± 0.07 
 Mid * 0.62 ± 0.07 0.65 ± 0.07 
 Post * 0.62 ± 0.07 0.62 ± 0.07 
Jump Power (w) Pre 978.3 ± 215.7 1024.7 ± 261.9 
 Mid * 997.4 ± 222.1 1077.4 ± 259.7 
 Post ‡ 979.3 ± 235.2 1025.7 ± 279.6 
Jump Velocity (m/s) Pre 1.4 ± 0.2 1.4 ± 0.2 
 Mid * 1.4 ± 0.2 1.4 ± 0.2 
 Post ‡ 1.3 ± 0.2 1.4 ± 0.2 
Leg Press (kg) Pre 251.9 ± 80.4 257.1 ± 106.8 
 Mid * 277.6 ± 81.8 283.6 ± 109.2 
 Post * 283.7 ± 80.7 284.9 ± 112.2 
Bench Press (kg) Pre 80.0 ± 30.6 77.9 ± 36.0 
 Mid * 83.7 ± 32.2 81.7 ± 38.3 
  Post * 82.8 ± 30.0 80.6 ± 35.0 
* Significantly different than Pre p≤0.05      
‡ Significantly different than Mid p≤0.05      
 
No significant group × time interactions were found for any of the aerobic 
capacity testing variables as shown in Table 12 (all p≥0.087).  ROTC had greater pre 
and post relative VO2 peak as compared to the control group (p=0.014), while both 
groups significantly increased over time (p=0.007).  Additional significant main effects 
for time were found as absolute VO2 and total time to exhaustion significantly increased 
while respiratory exchange ratio (RER) significantly decreased (all p≤0.022).   
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Table 12. Aerobic Capacity Testing Measures Over Time (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Absolute VO2 Peak (L/min) Pre 3.86 ± 0.97 3.59 ± 0.77 
 Post * 3.98 ± 0.98 3.68 ± 0.80 
Relative VO2 Peak (kg/mL/min) Pre 52.5 ± 7.8 # 47.1 ± 4.8 
 Post * 53.8 ± 8.1 #  48.5 ± 5.6 
Respiratory Exchange Ratio Pre 1.15 ± 0.06 1.16 ± 0.07 
 Post * 1.14 ± 0.07 1.12 ± 0.04 
Maximum Heart Rate (bpm) Pre 195 ± 8 196 ± 7 
 Post 195 ± 7 198 ± 8 
RPE Pre 18.1 ± 1.3 18.4 ± 1.4 
 Post 18.2 ± 1.1 18.8 ± 0.9 
Time to Exhaustion (min) Pre 10.5 ± 1.3 10.1 ± 1.7 
  Post * 11.6 ± 1.4 10.9 ± 1.7 
RPE: Respiratory Exchange Ratio       
* Significantly different than Pre p≤0.05       
# Significantly different than Controls p≤0.05       
 
Correlations between Biomarkers and Dependent Variables 
The secondary purpose of this study was to determine the relationship between 
PTH and sclerostin with bone variables. Few significant associations between PTH and 
DXA or pQCT were found for the whole group or when ROTC and control groups were 
considered separately. Pre and post non-dominant hip CSMI was positively correlated 
with PTH (both p≤0.029; Pearson’s r ranged from 0.365-0.371) when the whole group 
was considered.  In ROTC participants pre and post dominant hip bucking ratio was 
negatively correlated with PTH (both p≤0.024; Pearson’s r ranged from 0.529 - 0.541).  
Correlations between the pre and post PTH and pre and post total BSI, 4% trabecular 




Table 13. Correlation Matrix (r) for PTH and Bone Strength/Strain Indices Pre and 
Post Intervention. 
  Time 
4%         
Total BSI 
4% Trabecular 
BSI 38% SSI 66% SSI 
PTH (pg/mL) Pre -.129 -.010 -.055 -0.088 
PTH (pg/mL) Post -.008 .081 .017 0.125 
BSI: Bone Strength Index  SSI: Stress-Strain Index 
 
Sclerostin was significantly correlated with many DXA and pQCT variables.  
When correlating DXA variables and sclerostin for the ROTC participants, most of the 
86 variables considered were significantly associated.  In controls, only five of the 86 
DXA variables were correlated (p≤0.047; Pearson’s r ranged from 0.475 – 0.529).  In 
ROTC almost 75% of all pQCT variables were positively correlated with sclerostin (all 
p≤0.039; Pearson’s r ranged from 0.494 - 0.775), while in controls only nine of the 64 
pQCT variables were correlated (p≤0.047; Pearson’s r ranged from 0.474 – 0.547).  
Additionally, Table 14 displays the relationship between both pre and post serum 
sclerostin concentrations and all pre and post pQCT measures of bone strength (all 
p≤0.036).   
 
The last aim of the study included investigating the relationships between body 
composition, muscular strength and power measures, and aerobic fitness and the 
biomarkers, PTH and sclerostin.  PTH was not associated with any fat mass, % fat, 
Table 14. Correlation Matrix (r) for Sclerostin and Bone Strength/Strain Indices Pre 
and Post Intervention. 
  Time 
4%    
Total BSI 
4%    
Trabecular BSI 
38%   
SSI 
66%   
SSI 
Sclerostin (ng/mL) Pre .444** .351* .401* .533** 
Sclerostin (ng/mL) Post .434** .355* .407* .514** 
BSI: Bone Strength Index         * Significant correlations, p< 0.05 
SSI: Stress-Strain Index ** Significant correlations, p< 0.01 
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BFLBM or 66% tibia mCSA measures for either group (all p≥ 0.104; Pearson’s r 
ranged from -0.395 to 0.147).  Pre PTH was a positive correlate of pre relative VO2 
peak (p=0.031; Pearson’s r=0.510) but was negatively correlated with pre heart rate and 
rating of perceived exertion (RPE) (both p≤0.014; Pearson’s r was between -0.581 and -
0.587).  
Sclerostin was significantly correlated with many body composition and 
performance measures, which were group dependent.  Total body BFLBM was 
significantly positively correlated with sclerostin (Figure 8); while no significant 
correlations between fat mass (Figure 9) for sclerostin were found for either group.  Pre 
and post sclerostin concentrations were not significantly correlated with pre or post total 
%BF as shown in Figures 12 and 13 in Appendix H (both p=0.051). When correlating 
performance variables and sclerostin, ROTC had nearly two times more significant 
positive correlates as compared to controls (all p≤0.042; Pearson’s r ranged from 0.498 
- 0.804).  Bench press and sclerostin demonstrated the strongest positive association 
(p≤0.001; Pearson’s r = 0.804) as shown in Figure 16 in Appendix H, while jump power 
was the only jump variable correlated with sclerostin for any group, at any time point 
(all p≤0.015; Pearson’s r ranged from 0.565 to 0.676) as shown in Figure 14 in 
Appendix H.   
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Figure 8. Correlation Between Baseline Sclerostin and Total BFLBM. 
 
                            






















































As previously noted in Tables 13 and 14, PTH had very little association with 
measures of tibial bone strength while sclerostin was strongly correlated.  Similar strong 
correlations were found between calf muscle cross-sectional area (mCSA) at the 66% 
site and measures of bone strength.  Pre and post mCSA was significantly positively 
correlated with bone strength variables at all three tibia sites (all ≤0.003), as shown in 
Table 15. 
Table 15. Correlation Matrix (r) for mCSA and Bone Strength/Strain Indices Pre 
and Post Intervention. 
  Time 
4%                 
Total BSI 
4%            
Trabecular BSI 
38%   
SSI 
66%      
SSI 
mCSA (mm²) Pre 0.581** 0.482** 0.641** 0.604** 
mCSA  (mm²) Post 0.607** 0.522** 0.653** 0.640** 
mCSA: Muscle Cross-Sectional Area  SSI: Stress-Strain Index 
BSI: Bone Strength Index ** Significant correlations, p≤ 0.01 
 
Regression Analyses for Biomarkers and Measures of Bone Density and Quality 
 PTH and sclerostin were chosen as biomarkers due to the poor injury prediction 
capabilities of BTM in military personnel reported in the literature.  Simple linear 
regression was used to identify if each marker demonstrated predictive capabilities for 
the dependent variables total body aBMD, lumbar spine aBMD, hip aBMD and 
measures of tibia bone strength.   Table 16 shows the model outputs for each biomarker 
separately with the previously mentioned dependent variables.  Both dependent and 
independent variables used in the regression models were calculated percent changes 





Table 16. Regression Models for %∆ in Biomarkers and Bone Density and Quality. 
Dependent Variable Independent Variables β SEE R² 
Total Body aBMD Parathyroid Hormone -0.426 2.63681 0.182* 
Sclerostin 0.572 0.096995 0.327** 
Lumbar Spine L1-L4 
aBMD  
Parathyroid Hormone -0.083 1.5666 0.007 
Sclerostin 0.012 1.5719 0.000 
Dominant Femoral 
Neck aBMD 
Parathyroid Hormone -0.067 1.8065 0.005 
Sclerostin -0.12 1.7884 0.014 
Dominant Hip aBMD Parathyroid Hormone 0.193 1.0772 0.037 
Sclerostin -0.116 1.1404 0.014 
4% Total BSI Parathyroid Hormone -0.077 1.91646 0.006 
Sclerostin -0.047 1.90562 0.002 
4% Trabecular BSI Parathyroid Hormone 0.167 2.20009 0.028  
Sclerostin 0.053 2.22454 0.003 
38% SSI Parathyroid Hormone -0.175 1.26096 0.031 
Sclerostin -0.333 1.2373 0.111* 
66% SSI Parathyroid Hormone -0.102 6.23964 0.011 
Sclerostin 0.099 0.099 0.010 
* Significant  p≤ 0.05      
** Significant p≤ 0.01     
 
Sclerostin significantly predicted 38% SSI as shown above.  In Table 17, other 
potential predictors were added to investigate their potential predictive power.  These 
independent variables are common field measures of performance or body composition.  
%∆ total BF%, VO2 peak, leg press, bench press, and jump power were not 
independently significantly correlated with the %∆ in 38% SSI.  Multiple linear 
regression using the stepwise method was used to combine independent variables into 
predictive models. When the performance measures VO2 peak, leg press, bench press, 
and jump power were combined into a single predictive model they did not predict a 
significant about of the variance of %∆ in 38% SSI as shown in Table 18 (p=0.178).  
When sclerostin and 66% mCSA were combined into a predictive model they predicted 
nearly 45% of the variance of %∆ in 38% SSI as shown in Table 19 (p=0.003).   
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Figure 10. Correlation between Baseline Sclerostin and Total aBMD. 
 






















































Table 17. Potential Predictors of %∆ in 38% SSI.  
Dependent Variable Independent Variables β SEE R² 
38% SSI Sclerostin -0.333 1.2373 0.111* 
 Body Fat % -0.177 1.27561 0.031 
 VO2 Peak 0.241 1.25792 0.058 
 Leg Press 0.22 1.2989 0.048 
 Bench Press -0.039 1.29497 0.002 
 Jump Power -0.21 1.26714 0.044 
* Significant  p≤ 0.05    
** Significant p≤ 0.01    
 
Table 18. Predictive Model for %∆ in 38% SSI using Physical Performance Measures. 
Dependent Variable Independent Variables β  SEE R² 
38% SSI VO2 Peak 0.185 1.2591 0.19 
 Leg Press -0.362   
 Bench Press 0.314   
 Jump Power -0.038   
 
 
Table 19. Predictive Model for %∆ 38% SSI using %∆ Sclerostin and 66% mCSA. 
Dependent Variable Independent Variables β  SEE R² 
38% SSI Sclerostin 0.570 354.36 0.443** 
 66% mCSA 0.194   
** Significant p≤ 0.01 
 
Discussion  
Bone injuries cost the U.S. military over $100 million dollars per year (14) and 
are considered the leading cause of injury related discharge reported in both USMC and 
Naval basic training programs (53). Currently, the biomarkers used to predict bone 
injuries in military cohorts demonstrate poor predictive power and very inconsistent 
findings (3, 31, 35, 205).  The purpose of this study was to investigate Parathyroid 
Hormone and sclerostin as potential biomarkers of skeletal change during a military 
training intervention period using college-aged students enrolled in USMC and Naval 
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ROTC programs.  Neither biomarker demonstrated significant changes over time; 
however, %∆ in both PTH and sclerostin were significantly associated with %∆ in total 
body aBMD.  Sclerostin responses were also significantly correlated with %∆ in 38% 
SSI.  Sclerostin showed many significant positive associations with measures of bone 
density, quality, and strength, BFLBM, and performance measures.  Both groups 
exhibited significant losses in total BF %. Dominant femoral neck aBMD significantly 
increased in ROTC and decreased in controls. The dominant total hip aBMD 
significantly increased in ROTC; while, dominant total hip BMC significantly increased 
in controls after the eight week intervention. 
Parathyroid Hormone Responses 
 Parathyroid Hormone (PTH), in conjunction with Vitamin D, is a primary 
regulator of serum calcium ion concentrations and can negatively impact skeletal health 
if over or under produced (32).  Because of this relationship, serum PTH concentrations 
can be drastically altered by dietary calcium or seasonal effects of Vitamin D (111); 
unfortunately, many studies investigating military cohorts do not collect any dietary 
information or account for seasonal variations.  In this study, dietary calcium intake was 
above the recommended 1000 mg/day (203), so calcium deficiency is not expected to 
affect PTH responses.  The control group provided blood draws within two weeks of 
their matched ROTC participant, which allowed for the characterization of potential 
seasonal effects.   
The lack of group × time interactions in PTH responses described in the current 
study may have been due to either the short intervention length or the frequency of 
blood sampling.  Lester et al. (6) followed 69 college-aged physically inactive females 
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across an eight week exercise intervention period.  All participants were enrolled in 
either an aerobic training, resistance training, aerobic plus resistance training, or control 
group.  All groups demonstrated a significant initial rise in PTH levels from pre testing 
to four weeks; however, levels returned to baseline at the eight week post testing period.  
The authors did not provide any hypothesis for why this initial rise in PTH was 
observed for all groups. The current study also demonstrated no change from pre to 
eight week post testing period; however, since a mid or four week blood draw was not 
conducted inferences about the early PTH responses can not be made.  Evans et al. (35) 
reported opposite PTH responses in male Israeli Defense Forces recruits as PTH levels 
significantly decreased after eight weeks of basic training, but returned to baseline 
levels by the post (16 weeks) testing period.  Despite no sex differences in baseline 
calcium, Vitamin D, or PTH, male recruits exhibited a significant decrease in Vitamin 
D from pre to midway testing which was correlated with the significant drop in PTH 
reported by Evans et al. (35); however, they do not speculate as to why this 
counterintuitive finding emerged. 
Valimaki et al. (205) reported that elite Israeli infantry recruits who reported a 
stress fracture during a 14 week basic training program had mean PTH levels greater 
than pre or post mean PTH concentrations in the current study (56 pg/mL verses 48 
pg/mL). Chronically elevated PTH concentrations can result in excess calcium being 
mobilized from the mineral matrix and a subsequent reduction in the structural integrity 
of the bone, as observed in hyperparathyroidism (206).  However, intermittent PTH 
administration has been shown to stimulate bone formation by prolonging osteoblast 
survival (207).  Falk et al. (38) described PTH responses post exercise in boys and men.  
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At baseline both boys and men had similar resting values of PTH. Five minutes after a 
volume and intensity matched plyometrics circuit, both boys and men exhibited a 
significant positive PTH response, one hour later PTH responses had decreased and by 
24 hours post exercise bout, PTH levels had returned to baseline. This study did not 
mention any correction for plasma volume shifts and the acute PTH responses may be 
overestimated. Scott et al. (174) demonstrated that PTH increased with a single bout of 
treadmill running in healthy males; however, these authors note that the PTH response 
post exercise bout was much smaller than exogenous PTH injections provided in 
clinical settings to promote bone growth, and should not be considered as similar 
osteogenic responses.  This study also did not mention any adjustment for potential 
plasma volume shifts.   
High serum PTH levels have been found to be associated with stress fracture in 
military recruits (17, 34); however, contrary findings have been observed in athletic and 
military populations (31, 35, 177-179).  In the current study, PTH was significantly 
correlated with total body aBMD but not with any skeletal sites that are commonly 
susceptible to fracture such as the lumbar spine, hip, or tibia.  From the lack of 
consistency in the literature in both athletic and military populations and a small 
number of significant correlations to any DXA, pQCT, or performance measures in this 
study, PTH does not appear to provide any additional information to changes in bone 
over time in this particular cohort. 
Sclerostin Responses 
 If an exercise bout results in mechanical loading that exceeds the minimum 
strain threshold as described by Frost’s mechanostat theory (71), acute bone resorption 
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will occur followed by prolonged bone formation (1).  Osteocytes serve as the primary 
mechanosensing cells of the skeleton and are responsible for the skeletal response to 
mechanical stimuli.  These cells are also responsible for the secretion of sclerostin.  
Sclerostin can inhibit bone formation due to the disruption of Wnt signaling pathways 
resulting in fewer active osteoblasts (208).  Animal models consistently demonstrate 
sclerostin production is reduced with increases in mechanical loading, resulting in bone 
formation (182, 209); however, the sclerostin response to exercise in humans is less 
clear.   
No longitudinal studies to date have used a military population for the 
investigation of sclerostin responses to exercise, so inferences must come from other 
cohorts.  Many cross-sectional studies have shown that sclerostin increases post 
exercise bout (181, 185); however, perhaps this demonstrates the relationship between 
sclerostin and the brief resorptive state of the bone immediately post-exercise (38).  
Pickering et al. (183)  investigated sclerostin responses to 45 minutes of low-speed 
treadmill running in sedentary young women.  Serum sclerostin increased nearly 45% 
post exercise bout.  Falk et al. (38) characterized pre and post sclerostin responses to a 
plyometrics circuit in boys and men.  At baseline boys had significantly greater resting 
levels of sclerostin as compared to men; however, only men exhibited a significant 
increase in sclerostin five minutes post exercise and returned to baseline levels one hour 
post exercise.  It should be noted that neither Pickering et al. (183) or Falk et al. (38) 
mention any adjustments for plasma volume shifts.   A semi-longitudinal study 
conducted by Grasso et al. (186) followed professional cyclists throughout the Giro 
d'Italia, which is one of the most prominent road cycling events in the world.  Across 
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the 23 day stage race, serum sclerostin concentrations, which were adjusted for plasma 
volume shifts, significantly increased at each testing period.  However, no samples were 
collected in the days following the race, so true post exercise-bout inferences can not be 
made. Nine participants ran an ultra-distance race that averaged 34 hours of race time.  
Participants exhibited no changes in serum sclerostin from pre to post race; however, 
three day post race sclerostin levels were significantly reduced (186).   
To address the cross-sectional nature of most studies investigating sclerostin 
responses to exercise, Hinton et al. (42) followed men across two separate progressive 
12 month exercise programs.  Participants were enrolled in either a resistance training 
(RT) program or a plyometrics program.  The RT program consisted of two sessions per 
week including exercises that targeted the hips and spine such as squats, bent-over-row, 
dead lift, military press, lunges, and calf raises.  Progression was based off of a 6-week 
training block, followed by a rest week.  At the end of each block one repetition 
maximal efforts were recorded for all lifts and used to program the next block.  For the 
plyometrics protocol, participants met three times per week and engaged in high-impact 
and odd loading activities such as single leg jumps in multiple directions, box jumps, 
hurdles, and squat jumps.  Like the RT group, 6-week training blocks were used and at 
the end of each block maximal vertical jump was measured to track progress.  Both 
groups reported significant increases in total body and lumbar spine aBMD, while 
serum sclerostin was significantly reduced.  The consistent progression of exercise-
induced mechanical loading may have been why Hinton and colleagues (42) report a 
significant reduction in sclerostin as prolonged bone formation occurred.  In the current 
study, ROTC training protocols did incorporate exercise progression; however, due to 
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the short duration of the intervention most skeletal changes observed were very small 
and within the error of the DXA or pQCT.   
Despite no significant sclerostin response, valuable information can still be 
gathered from the biomarker’s positive associations with bone variables, specifically in 
ROTC participants. Sclerostin was significantly positively correlated with most of the 
86 DXA variables considered. Since sclerostin is produced by bone cells, greater 
concentrations should be observed in individuals with greater skeletal mass, which may 
partially be driving the number of significant correlations observed with DXA bone 
variables.  Interestingly, sclerostin was a stronger significant positive predictor of total 
aBMD and BMC in ROTC as compared to controls (r=0.798 vs. r=0.355 and r=0.845 
vs. r=0.256 respectively) despite no significant group differences between total body 
aBMD or BMC as shown in Figures 10 and 11.  Sclerostin was not positively associated 
with fat mass or %BF; which is contrast to other studies reporting positive correlations 
between sclerostin and aBMD and FM (232, 233). 
Krause et al. (234),  reported sclerostin and lean mass are directly related as 
rodents without sclerostin production capabilities demonstrated reduced lean mass. In 
the current study, sclerostin was positively associated with BFLBM for both groups, 
corroborating the findings by Krause et al. (234).  The association between sclerostin 
and BFLBM was group dependent, as the relationship was stronger in ROTC as 
compared to controls (r=0.786 vs. r=0.406).  These associations were also evident when 
considering measures of muscular power.  Baseline measures of sclerostin and bench 
press and leg press were strongly correlated as shown in Figure 15 and 16 in Appendix 
H, however, the relationship was stronger in ROTC as compared to controls.  Baseline 
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measures of sclerostin and jump power were significantly correlated in ROTC, but not 
controls. 
Bone density and bone geometry together play a critical role in skeletal integrity 
(58).  Sclerostin was strongly associated with measures of bone geometry and a 
significant positive predictor of bone strength indices at all tibia sites (R2 ranged from 
0.123-0.284).  This is very important to consider because distal tibial fractures are 
among the most common site in military cohorts (210, 211).  The sclerostin response 
was the only significant predictor of %∆ in 38% SSI, as compared to other commonly 
measured metrics in military studies, such as total BF% (skinfold calipers), VO2 peak 
(estimated from 2 mile run times), bench press, leg press, and jump power. (210, 211).  
Nearly 45% of %∆ in 38% SSI was predicted by %∆ sclerostin and 66% mCSA.  Due to 
the many positive correlations between sclerostin and bone variables, and the significant 
predictive capabilities of the biomarker for measures of bone strength, sclerostin should 
be considered in future studies investigating skeletal changes in this cohort. 
Areal Bone Mineral Density and Body Composition 
 Significant group × time interactions were found for the dominant femoral 
neck, and dominant total hip aBMD and BMC.  Dominant femoral neck aBMD 
significantly increased in ROTC and decreased in controls. The dominant total hip 
aBMD significantly increased in ROTC; while, dominant total hip BMC significantly 
decreased in controls.  Although the increases in dominant femoral neck and total hip 
aBMD in ROTC participants was statistically significant, the magnitude of these 
changes were less than the CV% of the DXA scanner, and are not considered 
significant.  Controls exhibited a significant decrease in dominant femoral neck aBMD 
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and in total hip BMC, both %∆ were only slightly above the CV% of the DXA scanner 
and are not considered clinically significant. Hip Structural Analysis (HSA) uses 
information gathered from the regional dual femur scans to estimate structural geometry 
from the planar image.  The analysis uses pixel density information and the measured 
BMC to make inferences about skeletal geometry (212).  The significant changes in hip 
BMC were most likely too small to translate to significant differences in HSA 
measures. Additionally, significant positive body composition changes were reported in 
both ROTC and control participants.  A significant time effect was observed as total 
BF% decreased while total body BFLBM increased from pre to mid points in both 
groups.  The magnitude of changes for total BF% exceeded the LSC for the DXA 
machine, however, the gain in BFLBM did not. 
The average %∆ in total BF% was 2.8% for ROTC and controls from pre to mid 
testing. This study utilized the DXA machine for body composition testing which 
provides excellent precision values.  Many other studies conducted with military 
cohorts use skinfold measurements to make assumptions about body composition and 
should be considered with caution. The magnitude of the changes in the current study 
were nearly three times greater than what was described by Evans et al. (35) who 
followed 194 Israeli Defense Forces recruits over four months. Evans et al. used 
skinfold measurements which may have not been a sensitive enough measure to detect 
small but significant total BF% changes.  Using DXA, Armstrong et al. (8) followed 31 
incoming freshman (plebes) at the United States Naval Academy in 2000.  Baseline 
characteristics were very similar to the current study’s cohort for age, height, body 
mass, and total body BMC (g); however, the average total BF% was nearly 5% lower 
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than our cohort (8).  These differences are most likely attributable to the frequency and 
intensity differences between the exercise interventions. Plebes summer basic training 
was described as 5 days/wk with 8.5 hours/day of physical training or drill training 
while the current study intervention was only 2 days/week with 2-3 hours/day of 
physical training or drill training.   
No significant changes were observed in total aBMD for either group. This may 
have been due to the short duration of the intervention.  Ahola et al. (213) followed 
women for 12 months with serial DXA scans to investigate the time course of exercise 
induced aBMD changes. Only women who reported high levels of progressive impact 
forces exhibited significant increases in aBMD at the femur after six months.  Stone et 
al. (214) followed women over 12 weeks of either yoga or kick boxing exercise 
interventions.  They suggested that 12 weeks was not enough time to observe significant 
changes in total body, lumbar spine, or dual femur aBMD; however, increased 
osteocalcin levels, a bone formation marker, were found. Zribi et al. (215) found that 
nine weeks of plyometrics performed only two times per week provided a sufficient 
stimulus to increase total body BMC and BTMs of bone formation but no significant 
increases in total body aBMD were detected.  Lester et al. (6) reported that eight weeks 
of either progressive aerobic/endurance training, resistance training, or the combination 
of each program was not enough time to detect significant changes in total body aBMD 
despite BTM and hormone profiles suggestive of bone formation.  The amount of 
impact loading and the progression of the exercise program are important factors to 
consider and as previously discussed, perhaps the military exercise intervention in this 
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study was too short and did not provide enough progression to result in an increase in 
aBMD in ROTC participants.   
Volumetric Bone Mineral Density 
No significant changes were found for all 4% and 38% pQCT variables.  These 
findings confirm those of Lester et al. (6) who followed participants during eight week 
exercise interventions.  Participants were divided between four separate groups, control, 
aerobic or endurance (ET), resistance training (RT), and combined.  At the 4% site only 
the aerobic group demonstrated a significant increase in total vBMD. In the current 
study, ROTC participants and nearly all control participants reported engaging in both 
ET and RT, and thus parallels from only the combined group should be drawn.  For the 
4%, 38%, and 66% pQCT variables in the combined groups, Lester et al. (6) reported 
no significant changes despite increases in the bone formation markers bone-specific 
alkaline phosphatase and osteocalcin.  Lester and colleagues (6) reported that total 
impact forces were greatest in running and suggested that perhaps the 4% site is more 
susceptible to changes due to volume of loading.  One additional consideration not 
addressed by Lester et al. (6), is perhaps the 4% site exhibited significant changes 
because of the type of bone present. Trabecular bone, which is mainly found at the 
distal ends of the long bones has a greater surface area to engage in turnover as 
compared to cortical bone which is primarily found at the 38% and the 66% sites.  
Potentially, that is why the trabecular rich 4% site was able to exhibit significant 
changes in such a short period of time as compared to the less metabolically active 
cortical bone sites. 
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Baseline pQCT measures in the current study were similar to uninjured military 
recruits as described by Davey et al. (216) who scanned over 1000 United Kingdom 
military recruits. They reported the 38% site being the most important for strong 
correlations to injury risk; however, since this study did not have any reported bone 
injuries site-specific correlations were not made.  Calf mCSA has been reported to be 
correlated with 38% and 66% SSI and fracture rates in athlete populations (4); however, 
Davey et al., (216) did not support these findings.  In order to investigate the 
relationship between calf mCSA, load attenuation, and fracture risk, Milgrom and 
colleagues (136) used a gastrocnemius fatigue model in military recruits.  Participants 
completed a 2-km run and 30-km desert march separately, with gastrocnemius fatigue 
and tibial compression strain rates being measured post-exercise.  Results suggested 
those with smaller calf mCSA experienced greater fatigue, and were not able to 
attenuate the load placed on the tibia, which resulted in greater bone strains.  Similar 
findings have been shown in endurance sports, as even early stages of calf fatigue have 
been shown to increase total bone load (137, 138).  Milgrom and colleagues (136) 
suggested those with greater calf mCSA would be capable of reducing bone loads and 
potentially reduce the risk of tibial fractures. These results support our findings, and 
contradict Davey et al., as pre and post 66% mCSA showed strong positive correlations 
with all tibial bone strength measures.  If Milgrom’s hypotheses are correct, then tibia 
fracture risk potentially decreased in both groups as mCSA increased over time.  
Physical Performance 
Both ROTC and controls were very active, with nearly 85% of all participants 
meeting the American College of Sports Medicine’s physical activity guidelines of at 
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least 150 min/wk of moderate or at least 75 min/wk of vigorous endurance training 
(ET), and at least 2 days/wk of resistance training (RT) (217, 218).  The inclusion of an 
activity matched control group is most likely the primary reason for the lack of 
significant group differences found.  It is also possible that controls increased their level 
of PA despite being encouraged to not make changes to their exercise routines for the 
duration of the study. 
Instead of using common field tests such as number of push ups or sit ups in one 
minute or a timed two mile run, this study utilized more maximum tests such as grip 
strength, jump performance, bench press, leg press, and maximal aerobic capacity.  This 
limits the ability to compare performance measures to other large scale studies; 
however, since both ROTC and controls were physically active most metrics were 
above average (218).  No significant changes occurred in the right hand grip strength; 
however, left hand grip strength decreased significantly at the post testing period.  
Despite this change, differences between the left and right hand grip strengths were less 
than 7% which has been considered to be a significant magnitude of asymmetry (219).  
Both ROTC and control group grip strength means were considered normal when 
compared with reference data specifically collected using the Jamar hand dynamometer 
(220). All jump metrics were within the 95% confidence interval for normative data for 
young adults (221).  Additionally, both ROTC and control bench press:body weight 
ratios were over 1.1 which is considered good and their leg press:body weight ratios 
were over 1:2.5 which is considered excellent (218).   
Nearly all measures of muscular strength and power increased from pre to 
midway testing periods for both groups; however, these measures either did not 
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continue to increase or returned to baseline values by the post testing period.  This 
pattern of change suggests both groups might have been engaging in more resistance 
training or power movements from the pre to the mid testing period as compared to the 
mid to the post testing periods.  Another possibility is from pre to midway testing 
performance gains were observed due to adaptations to the training program; however, 
perhaps due to a lack of training protocol progression, these gains were not sustained 
from mid to post testing.  Without a direct or indirect quantification of training 
protocols at the midway and post testing periods only speculations can be made 
regarding the potential changes in training type, time, intensity, volume, and frequency. 
ROTC had greater pre and post relative VO2 peaks as compared to the control 
group.  It should be noted that male and female controls had relative VO2 peak values 
categorized as average at the beginning and end the study.  ROTC male and female 
participants exhibited relative VO2 peak values in good and excellent categories at the 
beginning and end the study, with four ROTC males exhibiting values over 60 
mL/kg/min (218).  Evans et al. (35) reported an average 5% increase in estimated 
aerobic capacity over the 16 week basic training period; the current study demonstrated 
nearly half of that response observed by Evans.  Training intervention length and 
potential errors in the estimate of aerobic capacity from a two mile run is most likely 
responsible for this finding. 
Limitations 
There are several strengths and weakness to consider for this study.  The sample 
size is small compared to previous studies in military personnel, which presented some 
challenges and unique opportunities.  The primary issue with this small population was 
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the lack of injuries reported, which eliminates the ability to draw inferences about 
biomarker responses. However, due to the small sample size more precise measures 
were utilized such as DXA and pQCT as compared to heel ultrasound and skinfold 
measurements.  Additionally, maximum strength and power testing was conducted 
instead of using more traditional field tests, which minimizes the direct comparison to 
other large scale studies.  
Study duration should also be considered when interpreting these findings.  It is 
important to note that the acute responses of these biomarkers may not be indicative of 
the long term effects of the exercise on skeletal mass.  Studies that reported significant 
skeletal changes in conjunction with either PTH or sclerostin responses were often 6 or 
12 month interventions, and perhaps due to the short duration of the current study, 
skeletal and biomarker changes were too small to detect. 
Many questionnaires were used at the beginning of the study to assess health 
status and eligibility, including calcium intake and reported auxiliary physical activity 
questionnaires.  It would have been helpful to collect this information at the pre, 
midway, and post testing periods, which would allow for the description of potential 
changes in PA or calcium intake over time. 
Lastly, ROTC members are not yet commissioned military officers, instead they 
are college students who are preparing for a career in the military.  The findings of this 
study describe how ROTC programs may prepare these students for future enlistment 
but these findings should not be generalized to other types of basic training where the 




Chapter 5: Conclusions 
 
 
The purpose of this study was to determine the effects of an eight week military 
training intervention on PTH and sclerostin serum concentrations, and aBMD of the 
total body, dual femur, and lumbar spine, and bone geometry of the tibia, in healthy, 
college-aged USMC and Naval Reserve Officers’ Training Corps (ROTC) members 
compared to a matched control group. A secondary purpose was to determine the 
relationship between PTH and sclerostin and bone variables. Lastly, group differences 
in body composition, muscular strength and power measures, and aerobic fitness and 
their relationships to PTH and sclerostin were examined.   
Research Questions 
1. Will an eight week military training intervention period (MTIP) significantly 
alter PTH and sclerostin serum concentrations, and will these responses be 
different from those in a matched control group who does not participate in the 
MTIP? 
No significant group × time interactions, or main effects for time or group were 
found for either PTH or sclerostin. It was hypothesized that PTH would increase 
while sclerostin would decrease in ROTC but not controls.  The direction of 
biomarker responses was expected, but the magnitude of changes did not reach 
statistical significance for either group. 
2. Will an eight week MTIP result in significant total body aBMD changes and site 
specific aBMD changes at the lumbar spine and dual femur, and will these 
changes be different from those in a matched control group who does not 
participate in the MTIP? 
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Significant group × time interactions were found as dominant femoral neck 
aBMD significantly increased in ROTC and decreased in controls. The 
dominant total hip aBMD significantly increased in ROTC; while, dominant 
total hip BMC significantly increased in controls. It should be noted that none of 
these statistically significant changes in ROTC or controls exceeded the CV% 
for the DXA enough to be considered to be clinically significant. 
3. Will an eight week MTIP alter bone content, geometry, and strength of the 4%, 
38%, 66% non-dominant tibia sites, and will these changes be different from 
those in a matched control group who does not participate in the MTIP? 
No significant group × time interactions, or main effects for time or group were 
found for most of the pQCT variables.  A significant time effect was observed as 
66% total BMC and mCSA both increased from pre to post testing periods.  Due 
to the lack of interactions observed, hypotheses regarding pQCT variables were 
not confirmed. 
Sub Questions 
1. Will there be significant relationships between serum PTH and sclerostin and 
total body and site-specific aBMD, BFLBM and fat mass? 
PTH showed few significant correlations with measures of aBMD and body 
composition variables for both groups; however, sclerostin concentrations in 
ROTC participants were significantly correlated with many measures of aBMD, 
and BFLBM.   
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2. Will there be significant relationships between serum PTH and sclerostin and 
4%, 38%, 66% non-dominant tibia sites measures of bone strength and 
geometry? 
PTH was significantly associated with few pQCT variables. Sclerostin 
concentrations in ROTC participants demonstrated strong positive associations 
with pQCT variables, especially indices of bone strength at the 4%, 38%, and 
66% tibia sites.  Sclerostin was also a significant predictor of bone strength at 
the 4%, 38%, and 66% tibia sites confirming the proposed hypothesis 
3. Will there be significant relationships between serum PTH and sclerostin and 
muscular power and strength? 
PTH was not significantly correlated with any muscular power or strength 
measures for either group.  Sclerostin was significantly correlated with hand grip 
strength, bench press, leg press, and jump power at all testing points.  In general, 
the relationship between sclerostin and bone variables was stronger and 
incorporated a greater proportion of measures as compared to muscular strength 
and power performance tests. 
4. Will there be significant relationships between serum PTH and sclerostin and 
aerobic capacity? 
Sclerostin was significantly correlated with absolute VO2 peak at both testing 
points in ROTC only; while PTH was not consistently significantly associated 
with any variables.  Much like muscle performance testing, the relationship 
between sclerostin and bone variables was stronger and incorporated a greater 
proportion of measures as compared to aerobic capacity testing.  
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Clinical Significance 
Since no bone injuries were reported, associations between the biomarkers, PTH 
and sclerostin, cannot be made within this cohort; however, the positive correlations 
between sclerostin and measures of bone strength could still provide important 
information.  Since distal tibial fractures are among the most common in military 
cohorts and Davey et al. (216) report the 38% site being most important for injury risk it 
is encouraging to report that %∆ in 38% SSI was best predicted by %∆ sclerostin and 
66% mCSA as compared to other common field measures of BF% or performance 
measures.  
Control participants exhibited a statistically significant 1.02% decrease in 
dominant femoral neck aBMD which was close to the CV% of the DXA scanner.  
Although this change is rather small it could be argued that due to the age of the study 
population, any increase or decrease in aBMD is clinically important, as peak bone 
mass has not yet been reached. Peak aBMD is a significant predictor of fracture risk 
later in life (222-224); however, studies using pharmacological interventions report 
changes as small as 1-2% in aBMD can result in significant fracture reduction (225-
227).  It should be noted that many studies utilizing DXA do not report CV% values 
and thus their findings should be considered with caution. 
Hinton et al. (42) demonstrated, across a 12 month intervention, an average of 
4.5% reduction in sclerostin in the resistance trained group which coincided with a 
1.68% gain in lumbar spine aBMD, and 0.88% gain in total hip aBMD.  ROTC 
participants exhibited a 4.8% reduction in serum sclerostin concentrations, which 
corresponded with a 0.52% gain in the lumbar spine aBMD and a 0.64% gain in total 
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hip aBMD; however, these changes were not significant.  Armamentro-Villareal et al. 
(228), found after a 12 month weight loss study serum sclerostin increased by nearly 
10% which translated to a 2-3% loss in hip aBMD.  Few longitudinal studies have been 
conducted with sclerostin and many more need to be published before clinical 
recommendations for significant percent changes can be made.   
Recommendations for Future Research 
The correlations and predictive power of sclerostin may provide additional 
information for future studies investigating this population.  Interested investigators are 
encouraged to alter the current research design by lengthening the duration of the 
intervention, increasing the sample size, and increasing the frequency of blood 
sampling. 
Due to the recruitment of a physically active control group the general effects of 
exercise as a confounding variable were minimized.  This reduced the number of group 
differences observed; however, it also strengthened the integrity of interactions 
reported.  Currently, very little is published on sclerostin responses to longitudinal 
exercise interventions; however, the group specific associations between sclerostin and 
skeletal measures in ROTC is very interesting and deserving of further investigation. 
Lastly, maximum strength and power exercises have slowly become integrated 
into updated military training programs (50, 190, 192).  All branches of the military are 
starting to swap out long distance runs and sit ups for explosive, maximal effort power 
movements and future studies using this population should aim to reflect this transition 
with more testing of power and strength measures such as aerobic capacity, bench press, 
and leg press (192).  
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Appendix G: Dependent Variable Percent Change Tables 
 
Table 20. Total Body aBMD and Body Composition %∆ (means ± SD). 
  Time ROTC (n=18) Controls (n=18) 
Total Body aBMD (g/cm2) Pre-Mid -0.24 ± 2.23 -0.75 ± 1.32 
 Mid-Post -1.16 ± 4.62 0.35 ± 1.20 
 Pre-Post -1.35 ± 3.82 -0.39 ± 1.01 
Total Body BMC (g) Pre-Mid 0.20 ± 1.42 0.04 ± 1.53 
 Mid-Post 0.38 ± 1.06 -0.05 ± 1.08 
 Pre-Post 0.59 ± 0.95 0.00 ± 1.55 
Total Body % Fat Pre-Mid -2.99 ± 6.21 -2.68 ± 5.88 
 Mid-Post 0.10 ± 7.77 0.57 ± 5.91 
 Pre-Post -2.82 ± 9.27 -2.03 ± 7.70 
Total Body Fat Mass (kg) Pre-Mid -2.67 ± 6.69 -2.66 ± 7.16 
 Mid-Post 0.05 ± 7.96 0.42 ± 7.02 
 Pre-Post -2.68 ± 11.25 -2.14 ± 9.52 
Total Body BFLBM (kg) Pre-Mid 0.87 ± 2.21 0.97 ± 1.43 
 Mid-Post -0.20 ± 2.55 -0.39 ± 2.56 
  Pre-Post 0.69 ± 2.46 0.58 ± 2.80 
aBMD: Areal Bone Mineral Density (g/cm2)     
BMC: Bone Mineral Content (g)    
 
 














Table 21.  Regional aBMD and Body Composition %∆ (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Arms BMC (g) Pre-Mid 0.47 ± 2.96 0.34 ± 2.83 
 Mid-Post -0.31 ± 2.36 -0.65 ± 2.89 
 Pre-Post 0.22 ± 1.74 -0.25 ± 2.41 
Arms % Fat  Pre-Mid -3.41 ± 7.02 -3.12 ± 6.31 
 Mid-Post -1.20 ± 9.87 -0.70 ± 8.05 
 Pre-Post -4.32 ± 9.19 -3.75 ± 9.69 
Arms Fat Mass (kg) Pre-Mid -1.82 ± 7.92 -2.73 ± 6.71 
 Mid-Post -2.98 ± 11.53 -1.96 ± 9.80 
 Pre-Post -4.63 ± 12.71 -4.61 ± 11.05 
Arms BFLBM (kg) Pre-Mid 2.36 ± 3.89 1.29 ± 2.87 
 Mid-Post -1.89 ± 3.65 -1.17 ± 3.30 
 Pre-Post 0.58 ± 3.68 0.17 ± 3.70 
Legs BMC (g) Pre-Mid 0.03 ± 1.57 0.74 ± 14.51 
 Mid-Post -0.01 ± 1.50 1.77 ± 5.57 
 Pre-Post 0.03 ± 1.25 2.93 ± 12.01 
Legs % Fat Pre-Mid -2.94 ± 5.06 -6.31 ± 15.99 
 Mid-Post -0.92 ± 8.06 4.10 ± 8.79 
 Pre-Post -3.80 ± 8.68 -0.86 ± 7.13 
Legs Fat Mass (kg) Pre-Mid -2.45 ± 5.20 -4.39 ± 7.81 
 Mid-Post -0.27 ± 8.61 2.95 ± 6.81 
 Pre-Post -2.71 ± 10.08 -1.17 ± 9.10 
Legs BFLBM (kg) Pre-Mid 1.21 ± 2.92 5.22 ± 13.48 
 Mid-Post 0.88 ± 3.51 -2.93 ± 9.71 
 Pre-Post 2.09 ± 4.27 3.02 ± 12.06 
BMC: Bone Mineral Content (g) 









Table 22.  Lumbar Spine and Dual Hip aBMD (g/cm2) %∆ (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Lumbar Spine 1-4 Pre-Post 0.52 ± 1.33# -0.47 ± 1.60 
Dominant        
     Femoral Neck Pre-Post 0.76 ± 1.31# -1.02 ± 1.72 
     Trochanter Pre-Post 0.32 ± 1.77# -1.02 ± 2.17 
     Total Hip Pre-Post 0.63 ± 0.93# -0.26 ± 1.18 
Non-Dominant        
     Femoral Neck Pre-Post 0.01 ± 1.88 0.13 ± 1.67 
     Trochanter Pre-Post 0.59 ± 2.00 -1.03 ± 4.98 
     Total Hip Pre-Post 0.36 ± 1.07 0.14 ± 1.37 
# Significantly different than Controls p≤0.05 
 
 
Table 23.   Lumbar Spine and Dual Hip BMC (g) %∆ (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Lumbar Spine 1-4 Pre-Post 2.13 ± 7.62 0.30 ± 1.56 
Dominant 
       
     Femoral Neck Pre-Post 0.31 ± 1.72 -1.06 ± 2.37 
     Trochanter Pre-Post 0.86 ± 3.37 -2.18 ± 4.15 
     Total Hip Pre-Post 0.47 ± 1.29 -0.96 ± 1.56# 
Non-Dominant        
     Femoral Neck Pre-Post 0.56 ± 2.25 0.09 ± 1.39 
     Trochanter Pre-Post 1.01 ± 5.77 0.82 ± 3.82 
     Total Hip Pre-Post 0.38 ± 1.78 0.16 ± 1.16 









Table 24.   Hip Structural Analysis Variables %∆ (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Dominant Hip        
     Strength Index Pre-Post -4.50 ± 13.98 -0.06 ± 12.77 
     Buckling Ratio Pre-Post -25.53 ± 64.13 1.49 ± 39.84 
     Section Modulus (mm³) Pre-Post -1.50 ± 6.08 -1.07 ± 5.91 
     CSMI (mm⁴) Pre-Post -2.09 ± 5.86 -0.31 ± 4.69 
Non-Dominant        
     Strength Index Pre-Post -3.54 ± 15.40 0.04 ± 12.92 
     Buckling Ratio Pre-Post -15.57 ± 40.95 -11.99 ± 57.77 
     Section Modulus (mm³) Pre-Post -0.20 ± 3.94 -0.37 ± 3.63 
     CSMI (mm⁴) Pre-Post 1.59 ± 4.58 -0.71 ± 5.11 
CSMI: Cross-Section Moment of Inertia       
 
 
Table 25.  4% Non-Dominant Tibia pQCT Variables %∆ (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Total        
     BMC (mg/mm) Pre-Post -0.05 ± 0.94 0.01 ± 1.02 
     vBMD (mg/cm³) Pre-Post 0.12 ± 1.15 -0.37 ± 1.68 
     Area (mm²) Pre-Post -0.19 ± 1.62 0.37 ± 1.55 
Pre-Post 0.07 ± 1.36 -0.36 ± 2.26 
Trabecular        
     BMC (mg/mm) Pre-Post -0.28 ± 2.00 0.31 ± 1.50 
     vBMD (mg/cm³) Pre-Post 0.01 ± 0.72 -0.30 ± 1.40 
     Area  (mm²) Pre-Post -0.29 ± 2.08 0.60 ± 1.88 
     BSI (mg²/mm⁴) Pre-Post -0.27 ± 2.18 0.01 ± 2.20 
Periosteal Circ. (mm) Pre-Post -0.09 ± 0.81 0.19 ± 0.78 
BMC: Bone Mineral Content   BSI: Bone Strength Index 







Table 26.  38% Non-Dominant Tibia pQCT Variables %∆ (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Total        
     BMC (mg/mm) Pre-Post 0.30 ± 0.82 0.04 ± 0.47 
     vBMD (mg/cm³) Pre-Post 0.14 ± 0.37 0.02 ± 0.33 
     Area (mm²) Pre-Post 0.16 ± 0.59 0.02 ± 0.50 
Cortical        
     BMC (mg/mm) Pre-Post 0.25 ± 0.83 0.04 ± 0.52 
     vBMD (mg/cm³) Pre-Post 0.02 ± 0.39 -0.02 ± 0.36 
     Area  (mm²) Pre-Post 0.23 ± 1.10 0.05 ± 0.72 
     Thickness (mm) Pre-Post 0.18 ± 1.08 0.05 ± 0.70 
Periosteal Circ. (mm) Pre-Post 0.08 ± 0.29 0.01 ± 0.25 
Endosteal Circ. (mm) Pre-Post 0.02 ± 0.56 -0.01 ± 0.58 
iPolar (mm⁴) Pre-Post 0.39 ± 1.19 0.06 ± 0.71 
SSI (mm³) Pre-Post 0.08 ± 1.06 0.58 ± 1.45 
BMC: Bone Mineral Content  Circ: Circumference 
vBMD: Volumetric Bone Mineral Density  SSI: Stress Strain Index 
 
Table 27.  66% Non-Dominant Tibia pQCT Variables %∆ (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Total        
     BMC (mg/mm) Pre-Post 0.23 ± 0.56 0.13 ± 0.30 
     vBMD (mg/cm³) Pre-Post -2.51 ± 12.31 0.15 ± 0.63 
     Area (mm²) Pre-Post 1.71 ± 8.40 -0.02 ± 0.67 
Cortical        
     BMC (mg/mm) Pre-Post 0.06 ± 1.26 0.17 ± 0.46 
     vBMD (mg/cm³) Pre-Post -0.01 ± 0.81 0.06 ± 0.48 
     Area  (mm²) Pre-Post 0.07 ± 0.87 0.11 ± 0.44 
     Thickness (mm) Pre-Post -2.35 ± 11.66 0.14 ± 0.65 
Periosteal Circ. (mm) Pre-Post 0.96 ± 4.64 -0.01 ± 0.34 
Endosteal Circ. (mm) Pre-Post 2.39 ± 11.86 -0.05 ± 0.75 
iPolar (mm⁴) Pre-Post 2.55 ± 10.77 0.07 ± 0.79 
SSI (mm³) Pre-Post 1.80 ± 8.41 -0.13 ± 1.19 
Muscle CSA (mm²) Pre-Post 2.58 ± 2.28 0.76 ± 3.25 
BMC: Bone Mineral Content   Circ: Circumference 




Table 28.  Muscular Strength and Power Measures %∆ (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Right Hand Grip (kg) Pre-Mid -0.14 ± 7.51 0.73 ± 9.59 
 
Mid-Post -4.46 ± 9.99 -3.06 ± 6.56 
 Pre-Post -4.23 ± 8.73 -2.11 ± 9.66 
Left Hand Grip (kg) Pre-Mid -0.22 ± 9.12 2.06 ± 7.92 
 Mid-Post -5.57 ± 10.23 -6.14 ± 11.85 
 Pre-Post -5.14 ± 7.32 -3.72 ± 12.78 
Jump Height (in) Pre-Mid 3.91 ± 5.48 4.84 ± 6.08 
 Mid-Post -2.46 ± 6.89 -2.38 ± 4.04 
 Pre-Post 2.38 ± 4.64 2.66 ± 5.94 
Time in Air (sec) Pre-Mid 2.63 ± 3.93 2.53 ± 3.35 
 Mid-Post -1.17 ± 3.52 -0.74 ± 2.85 
 Pre-Post 1.86 ± 3.87 1.80 ± 3.47 
Jump Power (w) Pre-Mid 2.16 ± 3.92 4.99  6.42 
 Mid-Post -2.44 ± 6.16 -6.03 ± 6.92 
 Pre-Post -0.63 ± 5.56 -0.25 ± 6.82 
Jump Velocity (m/s) Pre-Mid 2.06 ± 3.77 3.49 ± 5.73 
 Mid-Post -3.05 ± 5.87 -4.71 ± 7.34 
 Pre-Post -1.39 ± 6.63 -1.14 ± 5.47 
Leg Press (kg) Pre-Mid 8.83 ± 10.28 9.59 ± 11.49 
 Mid-Post 1.98 ± 8.89 0.24 ± 7.49 
 Pre-Post 10.92 ± 13.08 10.06 ± 12.89 
Bench Press (kg) Pre-Mid 3.95 ± 5.04 3.17 ± 4.42 
 Mid-Post -0.18 ± 5.12 1.41 ± 8.91 
 Pre-Post 3.81 ± 6.86 4.46 ± 9.57 
 
Table 29.  Aerobic Capacity Testing Measures %∆ (means ± SD). 
 Time ROTC (n=18) Controls (n=18) 
Absolute VO2 Peak  (L/min) Pre-Post 2.64 ± 6.01 1.19 ± 4.32 
Relative VO2 Peak (kg/mL/min) Pre-Post 2.56 ± 4.80 1.41 ± 4.27 
Respiratory Exchange Ratio Pre-Post -1.27 ± 3.33 -3.99 ± 5.58 
Maximum Heart Rate (bpm) Pre-Post 0.30 ± 2.09 0.52 ± 2.67 
RPE Pre-Post -0.11 ± 5.99 1.82 ± 6.98 
Time to Exhaustion (min) Pre-Post 7.79 ± 8.85 5.05 ± 12.85 
RPE: Rating of Perceived Exertion       
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Appendix H: Sclerostin Scatterplots 
 




























































































































































25 75 125 175
P
re
 S
cl
er
o
st
in
 (
n
g
/m
L
)
Bench Press (kg)
ROTC r=0.804
Control r=0.478
